<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Doxycycline: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Doxycycline: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Doxycycline: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9393" href="/d/html/9393.html" rel="external">see "Doxycycline: Drug information"</a> and <a class="drug drug_patient" data-topicid="12402" href="/d/html/12402.html" rel="external">see "Doxycycline: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F163331"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Acticlate [DSC];</li>
<li>Avidoxy;</li>
<li>Doryx;</li>
<li>Doryx MPC;</li>
<li>Doxy 100;</li>
<li>Lymepak [DSC];</li>
<li>Mondoxyne NL;</li>
<li>Morgidox [DSC];</li>
<li>Okebo [DSC];</li>
<li>Oracea;</li>
<li>TargaDOX;</li>
<li>Vibramycin</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866676"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>APO-Doxy;</li>
<li>APO-Doxycycline MR;</li>
<li>Apprilon;</li>
<li>Doxycin;</li>
<li>Doxytab;</li>
<li>Periostat;</li>
<li>PRZ-Doxycycline;</li>
<li>TEVA-Doxycycline</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1047096"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antibiotic, Tetracycline Derivative</span></li></ul></div>
<div class="block don drugH1Div" id="F53462433"><span class="drugH1">Dosing: Neonatal</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing: </b>Doxycycline is available as hyclate, monohydrate, and calcium salts. All doses are expressed as doxycycline non–polymer-coated base. See specific manufacturer labeling for product details.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c74e9b7c-3d24-4a43-8fa5-6da3c93d72db">Anthrax</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anthrax:</b> Very limited data available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24777226']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24777226'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">Term neonates:</p>
<p style="text-indent:-2em;margin-left:6em;">Prophylaxis; post-exposure (inhalation or cutaneous); prior to susceptibility testing or penicillin-resistant strains: Oral: 2.2 mg/kg/dose every 12 hours for 60 days.</p>
<p style="text-indent:-2em;margin-left:6em;">Treatment:</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Cutaneous infection without systemic involvement: </i>
<b>Note:</b> Doxycycline is an option if first-line therapy (ie, ciprofloxacin) is unavailable or patient unable to tolerate; for naturally-occurring infection, usual treatment duration is 7 to 10 days; in the event of biological weapon exposure, additional therapy (as prophylaxis for inhaled spores) is necessary for a total course of 60 days from onset of illness.</p>
<p style="text-indent:-2em;margin-left:10em;">Oral: 2.2 mg/kg/dose every 12 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Systemic anthrax excluding meningitis:</i>
<b>Note:</b> Not recommended for meningitis or disseminated infection when meningitis cannot be ruled out. Doxycycline is an alternative to clindamycin as protein synthesis inhibitor and should be used in combination with a bactericidal antimicrobial (eg, fluoroquinolone, carbapenem, or vancomycin). Duration of therapy at least 14 days or longer until patient clinically stable. Additional therapy (as prophylaxis for inhaled spores) is necessary for a total course of 60 days from onset of illness.</p>
<p style="text-indent:-2em;margin-left:10em;">Initial: IV: Loading dose: 4.4 mg/kg once, then 2.2 mg/kg/dose every 12 hours; treat for ≥2 to 3 weeks until condition stable.</p>
<p style="text-indent:-2em;margin-left:10em;">Step-down: Oral: 2.2 mg/kg/dose every 12 hours.</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F163349"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing: </b>Doxycycline is available as hyclate, monohydrate, and calcium salts. Modified polymer-coated tablet (Doryx MPC) is not substitutable with other doxycycline products on a milligram-to-milligram basis; modified polymer-coated tablet (Doryx MPC) 120 mg is equivalent to conventional delayed-release tablet 100 mg. All doses are expressed as doxycycline non–polymer-coated base; dosage conversion necessary if using polymer-coated product (Doryx MPC). See specific manufacturer labeling for product details.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical considerations:</b> Doxycycline was traditionally avoided in ages &lt;8 years, but use has more recently been accepted for short courses (&lt;21 days) for all ages when necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bradley.2','lexi-content-ref-33251700','lexi-content-ref-AAP.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bradley.2','lexi-content-ref-33251700','lexi-content-ref-AAP.2021'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>General dosing:</b> Children and Adolescents: Oral, IV: 2.2 mg/kg/dose every 12 hours; maximum dose: 100 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.2021','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.2021','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ce2c669f-3aef-42bf-815c-cd8f32908ea9">Acne vulgaris, moderate to severe, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acne vulgaris, moderate to severe, treatment:</b> Limited data available: Children ≥8 years and Adolescents: Oral: 50 to 100 mg once or twice daily or 150 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23637225']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23637225'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c74e9b7c-3d24-4a43-8fa5-6da3c93d72db">Anthrax</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anthrax </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24777226']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24777226'])">Ref</a></span>): <b>Note:</b> Consult public health officials for event-specific recommendations.</p>
<p style="text-indent:-2em;margin-left:4em;">Prophylaxis; postexposure (inhalation or cutaneous); prior to susceptibility testing or penicillin-resistant strains: <b>Note:</b> Doxycycline is a preferred option or ciprofloxacin: Infants, Children, and Adolescents: Treatment duration: 60 days.</p>
<p style="text-indent:-2em;margin-left:6em;">Patient weight &lt;45 kg: Oral: 2.2 mg/kg/dose every 12 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">Patient weight ≥45 kg: Oral: 100 mg every 12 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Treatment; susceptible strains:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Cutaneous infection without systemic involvement: </i>
<b>Note:</b> Doxycycline is an option if first-line therapy (ie, ciprofloxacin) is unavailable or patient unable to tolerate; for naturally-occurring infection, usual treatment duration is 7 to 10 days; in the event of biological weapon exposure, additional therapy (as prophylaxis for inhaled spores) is necessary for a total course of 60 days from onset of illness.</p>
<p style="text-indent:-2em;margin-left:8em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:10em;">Patient weight &lt;45 kg: Oral: 2.2 mg/kg/dose every 12 hours.</p>
<p style="text-indent:-2em;margin-left:10em;">Patient weight ≥45 kg: Oral: 100 mg every 12 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Systemic anthrax, excluding meningitis: </i>
<b>Note:</b> Not recommended for meningitis or disseminated infection when meningitis cannot be ruled out. Doxycycline is an alternative to clindamycin as protein synthesis inhibitor and should be used in combination with a bactericidal antimicrobial (eg, fluoroquinolone, carbapenem, vancomycin). Duration of therapy at least 14 days or longer until patient clinically stable; additional therapy (as prophylaxis for inhaled spores) is necessary for a total course of 60 days from onset of illness.</p>
<p style="text-indent:-2em;margin-left:8em;">Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:10em;">Patient weight &lt;45 kg:</p>
<p style="text-indent:-2em;margin-left:12em;">Initial: IV: Loading dose: 4.4 mg/kg once, then 2.2 mg/kg/dose every 12 hours; may transition to oral therapy for patients without signs of active infection who are able to tolerate oral therapy and patient/caregiver adherent to therapy.</p>
<p style="text-indent:-2em;margin-left:12em;">Step-down: Oral: 2.2 mg/kg/dose every 12 hours.</p>
<p style="text-indent:-2em;margin-left:10em;">Patient weight ≥45 kg:</p>
<p style="text-indent:-2em;margin-left:12em;">Initial: IV: Loading dose: 200 mg once, then 100 mg every 12 hours; may transition to oral therapy for patients without signs of active infection who are able to tolerate oral therapy and patient/caregiver adherent to therapy.</p>
<p style="text-indent:-2em;margin-left:12em;">Step-down: Oral: 100 mg every 12 hours.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="49929a72-f7cf-4de4-8d52-7a1d857c693e">Brucellosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Brucellosis:</b> Limited data available: Children ≥8 years and Adolescents: Oral: 2.2 mg/kg/dose twice daily for at least 6 weeks; maximum dose: 100 mg/dose; use in combination with rifampin; for serious infections, gentamicin should be added for initial 1 to 2 weeks and therapy may be extended for up to 4 to 6 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bradley.2','lexi-content-ref-AAP.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bradley.2','lexi-content-ref-AAP.2021'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3446cebf-5a56-4f8c-a0a6-e28356e0fac3">Chlamydial infections, uncomplicated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chlamydial infections, uncomplicated (sexually transmitted <i>C. trachomatis)</i>:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥8 years: Oral: 2.2 mg/kg/dose twice daily for 7 days. Maximum dose: 100 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bradley.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bradley.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents: Oral: 100 mg twice daily for 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7130fea1-030c-4496-822e-505264056ed4">Cholera, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cholera (<i>Vibrio cholerae</i>), treatment: Note:</b> Due to resistance concerns, antibiotic choice during an outbreak or epidemic should be guided by local isolate susceptibility (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.1','lexi-content-ref-GTFCC.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.1','lexi-content-ref-GTFCC.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children &lt;6 years: Oral: 4 mg/kg as a single dose in combination with hydration; maximum dose: 300 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.1','lexi-content-ref-GTFCC.1','lexi-content-ref-AAP.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.1','lexi-content-ref-GTFCC.1','lexi-content-ref-AAP.2021'])">Ref</a></span>). <b>Note:</b> In children ≥6 years of age, a higher dose of 6 mg/kg was associated with a slightly shorter duration of diarrhea; data with 6 mg/kg are not available for children &lt;6 years of age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1088099']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1088099'])">Ref</a></span>). Although doses as low as 2 mg/kg have been recommended, they represent a lower dosing strategy as compared to 300 mg adult dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.1','lexi-content-ref-GTFCC.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.1','lexi-content-ref-GTFCC.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥6 years and Adolescents: Oral: 4 to 6 mg/kg as a single dose in combination with hydration; maximum dose: 300 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1088099','lexi-content-ref-AAP.2021','lexi-content-ref-708024','lexi-content-ref-29790841']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1088099','lexi-content-ref-AAP.2021','lexi-content-ref-708024','lexi-content-ref-29790841'])">Ref</a></span>). <b>Note:</b> Although doses as low as 2 mg/kg have been recommended, they represent a lower dosing strategy as compared to 300 mg adult dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.1','lexi-content-ref-GTFCC.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.1','lexi-content-ref-GTFCC.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d6b46673-8570-4914-ad98-b96bd4dd105b">Endocarditis, prophylaxis before invasive dental procedures</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Endocarditis, prophylaxis before invasive dental procedures (alternative agent): </b>Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Alternative agent for use in patients with penicillin or ampicillin allergy. Recommended only in patients who are at highest risk for infective endocarditis (IE) or adverse outcomes (eg, history of IE, cardiac valve repair using prosthetic valves or material, unrepaired cyanotic congenital heart disease [CHD], left ventricular assist device or implantable heart, repaired CHD with prosthetic material or device during first 6 months after procedure, pulmonary artery valve or conduit placement [eg, Melody valve, Contegra conduit], repaired CHD with residual defects at the site or adjacent to site of prosthetic patch or device, heart transplant recipients with cardiac valvulopathy) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26373317','lexi-content-ref-33853363','lexi-content-ref-28315732']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26373317','lexi-content-ref-33853363','lexi-content-ref-28315732'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: Oral: 2.2 mg/kg as a single dose administered 30 to 60 minutes prior to dental procedure; maximum dose: 100 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33853363']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33853363'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0676402d-6bcc-48b1-a3ce-53f79c692b71">Lyme disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Lyme disease (<i>Borrelia </i>spp. infection):</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Prophylaxis, postexposure</i>: Infants, Children, and Adolescents: Oral: 4.4 mg/kg/dose as a single dose; maximum dose: 200 mg/dose. <b>Note: </b>Prophylaxis is used only in patients who meet <b>all</b> of the following criteria for a high-risk bite: <i>Ixodes</i> spp. tick attached for ≥36 hours, prophylaxis can be given within 72 hours of tick removal, and tick bite occurred in a highly endemic area (ie, local rate of <i>Ixodes</i> spp. tick infection with <i>Borrelia burgdorferi </i>is ≥20%) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33251700']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33251700'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Treatment: </i>Infants, Children, and Adolescents: Oral: 2.2 mg/kg/dose twice daily; maximum dose: 100 mg/dose. Duration of therapy depends on clinical syndrome; treat erythema migrans for 10 days; borrelial lymphocytoma for 14 days; meningitis, radiculopathy, cranial nerve palsy, or carditis for 14 to 21 days; arthritis (initial, recurrent, or refractory) for 28 days; and acrodermatitis chronica atrophicans for 21 to 28 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33251700']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33251700'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0acddc60-f298-46aa-ab90-6ccb55be7fd5">Malaria</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Malaria:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Prophylaxis: Children ≥8 years and Adolescents: Oral: 2.2 mg/kg/dose once daily starting 1 to 2 days before travel to the area with endemic infection, continuing daily during travel and for 4 weeks after leaving endemic area; maximum daily dose: 100 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Tan.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Tan.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Treatment: Children and Adolescents: Oral, IV: 2.2 mg/kg/dose twice daily for 7 days; maximum dose: 100 mg/dose; use in combination with quinine sulfate (plus primaquine for <i>Plasmodium vivax</i>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2'])">Ref</a></span>).<b> Note:</b> Use of doxycycline in children &lt;8 years should be reserved for when alternatives are not available or are not tolerated; benefits should outweigh risks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ea1fb147-f9c4-4ecd-8ee0-4eaeb1d94d20">Pneumonia, community-acquired; presumed or proven atypical infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pneumonia</b>, <b>community-acquired; presumed or proven atypical infection (<i>Mycoplasma pneumoniae, Chlamydophila pneumoniae)</i>: </b>Children ≥8 years and Adolescents: Oral: 1 to 2 mg/kg/dose twice daily for 10 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21880587']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21880587'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ee55d874-2d0b-4f70-bab7-3457c401ca26">Q fever</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Q fever <i>(</i>
<i>Coxiella burnetii)</i></b>: Children and Adolescents: Oral: 2.2 mg/kg/dose twice daily for 14 days; maximum dose: 100 mg/dose. In children &lt;8 years with mild or uncomplicated disease, may consider treatment duration of 5 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23535757','lexi-content-ref-34135692']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23535757','lexi-content-ref-34135692'])">Ref</a></span>). For treatment of endocarditis or chronic disease in patients ≥8 years of age, use in combination with hydroxychloroquine for 18 to 36 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bradley.2','lexi-content-ref-34135692','lexi-content-ref-AAP.2021','lexi-content-ref-28938256']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bradley.2','lexi-content-ref-34135692','lexi-content-ref-AAP.2021','lexi-content-ref-28938256'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fc6def1e-d5b2-4504-8f95-87ed6e9e386f">Skin/soft tissue infections; MRSA or community-acquired cellulitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Skin/soft tissue infections; MRSA or community-acquired cellulitis (purulent) </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21217178']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21217178'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥8 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">≤45 kg: Oral: 2 mg/kg/dose every 12 hours for 5 to 10 days.</p>
<p style="text-indent:-2em;margin-left:6em;">&gt;45 kg: Oral: 100 mg twice daily for 5 to 10 days.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="44d1dede-6e67-4476-9345-58b985b67442">Tickborne rickettsial disease, ehrlichiosis, or anaplasmosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Tickborne rickettsial disease (Rocky Mountain spotted fever), ehrlichiosis, or anaplasmosis:</b> Children and Adolescents: Oral, IV: 2.2 mg/kg/dose every 12 hours; maximum dose: 100 mg/dose; treat for minimum of 5 to 7 days; continue for at least 3 days after defervescence and clinical improvement observed. Severe or complicated disease may require longer treatment; anaplasmosis should be treated for 10 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27172113']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27172113'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bf64d97c-215c-415e-9c7b-86a9dd06850a">Tularemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Tularemia (</b>
<i>
<b>Francisella tularensis</b></i>
<b>):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Postexposure prophylaxis: </i>Children and Adolescents: Oral: 2.2 mg/kg/dose every 12 hours for 14 days; maximum dose: 100 mg/dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11386933']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11386933'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Treatment </i>
<i>(alternative agent):</i> Children and Adolescents: Oral, IV: 2.2 mg/kg/dose every 12 hours for 14 to 21 days; maximum dose: 100 mg/dose. For bioterrorism events: Contained casualty: 14 to 21 days of therapy, with therapy initiated IV; Mass casualty: 14 days of oral treatment is recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15677845','lexi-content-ref-CDC.2022c','lexi-content-ref-11386933']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15677845','lexi-content-ref-CDC.2022c','lexi-content-ref-11386933'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51094224"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Children and Adolescents: IV, Oral: Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Altered kidney function:</b>
<i>Mild to severe kidney impairment:</i> Based on adult information, no dosage adjustment is necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-4767570','lexi-content-ref-4564509']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-4767570','lexi-content-ref-4564509'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Hemodialysis, intermittent:</b> Poorly dialyzed (0% to 5%); based on adult information, no supplemental dose or dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6626415','lexi-content-ref-4564509','lexi-content-ref-4584946']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6626415','lexi-content-ref-4564509','lexi-content-ref-4584946'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Peritoneal dialysis:</b> Poorly dialyzed; based on adult information, no dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-4584946']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-4584946'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Continuous renal replacement therapy (CRRT):</b> Based on adult information, no dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19397464']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19397464'])">Ref</a></span>).</p></div>
<div class="block dohp drugH1Div" id="F51117864"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F163336"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9393" href="/d/html/9393.html" rel="external">see "Doxycycline: Drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b></b>
<b>Dosing: </b>Doxycycline is available as hyclate, monohydrate, and calcium salts. All doses are expressed as doxycycline base.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Usual dosage range:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> IR and most ER formulations: 100 to 200 mg/day in 1 to 2 divided doses. <b>Note:</b> 60 mg of modified polymer-coated tablet (Doryx MPC) is equivalent to 50 mg conventional delayed-release tablet and 120 mg of modified polymer-coated tablet (Doryx MPC) is equivalent to 100 mg conventional delayed-release tablet.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 100 mg every 12 hours. <b>Note: </b>IV form may cause phlebitis.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5c4354e0-2178-427d-a042-9beb609e2523">Acne vulgaris, inflammatory, moderate to severe</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acne vulgaris, inflammatory, moderate to severe (off-label dose): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Use in combination with topical acne therapy. Treatment should ideally be limited to 3 to 4 months to minimize the risk of resistance (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26897386']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26897386'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral: </b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Immediate release:</i> 50 to 100 mg twice daily <b>or</b> 100 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26897386','lexi-content-ref-Graber.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26897386','lexi-content-ref-Graber.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Extended release:</i> 100 mg twice daily on day 1, then 100 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26897386','lexi-content-ref-Graber.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26897386','lexi-content-ref-Graber.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Subantimicrobial dosing:</i> 20 mg twice daily (immediate release) <b>or</b> 40 mg once daily (delayed release) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26091383','lexi-content-ref-12707093']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26091383','lexi-content-ref-12707093'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="60e9d2ac-8a42-4447-963b-6e516db3e471">Actinomycosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Actinomycosis (alternative agent):</b>
<b>Oral, IV:</b> 100 mg every 12 hours. Optimal duration is uncertain; some experts suggest total durations of 2 to 6 months for mild infection and 6 to 12 months (including 4 to 6 weeks of parenteral therapy) for severe or extensive infection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Brook.2020','lexi-content-ref-34391332']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Brook.2020','lexi-content-ref-34391332'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="95586163-358a-45ce-9340-7ab49f9553ab">Anaplasmosis and ehrlichiosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anaplasmosis and ehrlichiosis (off-label use)</b>: <b>Oral, IV:</b> 100 mg twice daily for 10 days or at least 3 days after resolution of fever (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27172113','lexi-content-ref-17029130']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27172113','lexi-content-ref-17029130'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c74e9b7c-3d24-4a43-8fa5-6da3c93d72db">Anthrax</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anthrax: Note:</b> Consult public health officials for event-specific recommendations.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Inhalational (postexposure prophylaxis):</i>
<b>Oral:</b> 100 mg every 12 hours; duration depends on anthrax vaccine status and series completion, age, immune status, and pregnancy/breastfeeding status. For those who have not previously received an anthrax vaccine, duration ranges from 42 to 60 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31834290']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31834290'])">Ref</a></span>). Some experts favor longer durations of prophylaxis (eg, total of 3 to 4 months) for patients who are immunocompromised or remain unvaccinated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Wilson.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Wilson.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Anthrax vaccine should also be administered to exposed individuals (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31834290','lexi-content-ref-24447897']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31834290','lexi-content-ref-24447897'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Cutaneous (without systemic involvement), treatment:</i>
<b>Oral:</b> 100 mg every 12 hours for 7 to 10 days after naturally acquired infection; treat for 60 days for bioterrorism-related cases. <b>Note:</b> Treat patients with extensive edema or cutaneous lesions of the head or neck with a parenteral regimen recommended for systemic involvement (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24447897']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24447897'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Systemic (meningitis excluded; alternative agent), treatment:</i>
<b>IV:</b> Initial: 200 mg as a single dose, then 100 mg every 12 hours, in combination with a bactericidal agent; treat for 2 weeks or until clinically stable, whichever is longer. <b>Note:</b> Antitoxin should also be administered for systemic anthrax. Following a course of IV combination therapy, patients exposed to aerosolized spores require oral doxycycline monotherapy to complete a total antimicrobial course of 60 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24447897']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24447897'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="452a5fca-911d-417a-b625-1b0f7a95ccab">
<i>Bartonella</i> spp. infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Bartonella</i></b>
<b> spp. </b>
<b>infection: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Patients with HIV:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>
<b>Treatment:</b></i>
<b>Note: </b>Duration of therapy is ≥3 months; continuation of therapy depends on clinical condition and response to therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-USHHS.2015']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-USHHS.2015'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Bacillary angiomatosis, cat scratch disease, peliosis hepatis, bacteremia, and osteomyelitis:</i>
<b>Oral, IV:</b> 100 mg every 12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-USHHS.2015']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-USHHS.2015'])">Ref</a></span>). <b>Note: </b>Some experts use in combination with gentamicin for the first 2 weeks of therapy for patients with <i>Bartonella </i>bacteremia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15155180','lexi-content-ref-Spach.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15155180','lexi-content-ref-Spach.3'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>CNS infections:</i>
<b>Oral, IV:</b> 100 mg every 12 hours; may use in combination with rifampin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-USHHS.2015','lexi-content-ref-Spach.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-USHHS.2015','lexi-content-ref-Spach.3'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Endocarditis:</i>
<b>Oral, IV:</b> 100 mg every 12 hours; use in combination with rifampin for the first 6 weeks (or gentamicin for first 2 weeks if rifampin cannot be used) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-USHHS.2015','lexi-content-ref-Spach.2019b']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-USHHS.2015','lexi-content-ref-Spach.2019b'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Other severe infections:</i>
<b>Oral, IV:</b> 100 mg every 12 hours in combination with rifampin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-USHHS.2015']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-USHHS.2015'])">Ref</a></span>); some experts initiate with IV therapy and transition to oral when patient becomes clinically stable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Spach.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Spach.3'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Suppressive therapy:</i> Note: </b>For patients who experience a relapse after receiving a ≥3-month course of primary treatment.</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Oral:</b> 100 mg every 12 hours. Continue until patient has received ≥3 months of therapy and CD4 count is &gt;200 cells/mm<sup>3 </sup>for ≥6 months; some experts discontinue therapy only if <i>Bartonella</i> titers have also decreased 4-fold (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-USHHS.2015']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-USHHS.2015'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Patients without HIV:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Bacteremia without endocarditis: </i>
<b>Oral:</b> 200 mg once daily <b>or</b> 100 mg twice daily for 4 weeks with gentamicin (or rifampin if gentamicin cannot be used) for first 2 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12821469','lexi-content-ref-15155180','lexi-content-ref-Spach.2019a']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12821469','lexi-content-ref-15155180','lexi-content-ref-Spach.2019a'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Cat scratch disease, CNS infection, and neuroretinitis: </i>
<b>Oral, IV:</b> 100 mg twice daily in combination with rifampin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15155180']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15155180'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Endocarditis:</i>
<b>Oral, IV:</b> 100 mg every 12 hours for 3 months; use in combination with rifampin for the first 6 weeks (or gentamicin for first 2 weeks if rifampin cannot be used) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15155180','lexi-content-ref-Spach.2019b']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15155180','lexi-content-ref-Spach.2019b'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bb1f0aaf-41ff-4651-ad53-d81e2f072c7d">Bite wound infection, prophylaxis or treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bite wound infection, prophylaxis or treatment (animal or human bite) (alternative agent) (off-label use):</b>
<b>Oral, IV:</b> 100 mg twice daily in combination with an appropriate agent for anaerobes. Duration is 3 to 5 days for prophylaxis; for established infection, continue for 1 to 2 days after resolution, typically 5 to 14 days total, although deep or complicated infections may require a longer duration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Baddour.2019a','lexi-content-ref-Baddour.2019b','lexi-content-ref-24947530']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Baddour.2019a','lexi-content-ref-Baddour.2019b','lexi-content-ref-24947530'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="49929a72-f7cf-4de4-8d52-7a1d857c693e">Brucellosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Brucellosis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Treatment:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Endocarditis or neurobrucellosis: Limited data available: <b>IV, Oral:</b> 100 mg twice daily for at least 12 weeks (may be needed for up to 6 months); use as part of an appropriate combination regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33650077','lexi-content-ref-34734902','lexi-content-ref-28143754','lexi-content-ref-28768443']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33650077','lexi-content-ref-34734902','lexi-content-ref-28143754','lexi-content-ref-28768443'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Uncomplicated (nonfocal): <b>Oral:</b> 100 mg twice daily for 6 weeks as part of an appropriate combination regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18162038','lexi-content-ref-33650077','lexi-content-ref-16575723','lexi-content-ref-18321957']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18162038','lexi-content-ref-33650077','lexi-content-ref-16575723','lexi-content-ref-18321957'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Spondylitis: <b>Oral:</b> 100 mg twice daily for at least 12 weeks as part of an appropriate combination regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33650077','lexi-content-ref-7695265']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33650077','lexi-content-ref-7695265'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Postexposure prophylaxis (high-risk laboratory exposure):</i>
<b>Oral:</b> 100 mg twice daily with rifampin for 3 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2012']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2012'])">Ref</a></span>); for exposure to <i>B. abortus</i> RB51 strains, some experts give doxycycline plus trimethoprim-sulfamethoxazole (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bosilkovski.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bosilkovski.2019'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="144bfda0-cd07-4b30-a02a-f08025a0fc36">Bullous pemphigoid</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bullous pemphigoid (off-label use): Oral:</b> 100 mg twice daily, in combination with topical or systemic corticosteroids (EADV [Borradori 2022]; Williams 2017).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7130fea1-030c-4496-822e-505264056ed4">Cholera, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cholera (<i>Vibrio cholerae</i>), treatment (adjunctive agent): Note:</b> For use in combination with rehydration therapy in patients with moderate to severe volume depletion. Due to resistance concerns, antimicrobial therapy during an outbreak or epidemic should be guided by isolate susceptibility (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2015']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2015'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 300 mg as a single dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2015']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2015'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bbd52e21-dcfe-472c-a480-3587971723ab">Chronic obstructive pulmonary disease, acute exacerbation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic obstructive pulmonary disease, acute exacerbation (off-label use):</b>
<b>Oral:</b> 100 mg once or twice daily for 5 to 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3492164','lexi-content-ref-19875685','lexi-content-ref-GOLD.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3492164','lexi-content-ref-19875685','lexi-content-ref-GOLD.1'])">Ref</a></span>). <b>Note:</b> Some experts reserve for patients with uncomplicated COPD (eg, &lt;65 years of age without major comorbidities, FEV<sub>1</sub> &gt;50% predicted, infrequent exacerbations) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17878469','lexi-content-ref-19038881']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17878469','lexi-content-ref-19038881'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d6b46673-8570-4914-ad98-b96bd4dd105b">Endocarditis, prophylaxis before invasive dental procedures</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Endocarditis, prophylaxis before invasive dental procedures (alternative agent for patients with penicillin allergy) (off-label use):</b>
<b>Oral:</b> 100 mg administered 30 to 60 minutes prior to procedure; if inadvertently not given prior to the procedure, may be administered up to 2 hours after the procedure. <b>Note:</b> Reserve for select situations (cardiac condition with the highest risk of adverse endocarditis outcomes and procedure likely to result in bacteremia with an organism that can cause endocarditis) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17446442']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17446442'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="65cfe90c-560a-4faa-a54f-70183efe21d9">Endocarditis, treatment, oral step-down therapy in patients who inject drugs</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Endocarditis, treatment, oral step-down therapy in patients who inject drugs (alternative agent) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Not first-line treatment; data are limited. Reserve use for patients who inject drugs who had initial clinical improvement with IV treatment for methicillin-resistant <i>S. aureus</i> or penicillin allergy for methicillin-susceptible <i>S. aureus</i> infection but cannot complete IV standard of care therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36043414','lexi-content-ref-36052413']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36043414','lexi-content-ref-36052413'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral: </b>100 mg twice daily for a total duration, including initial IV therapy, of 6 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36043414']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36043414'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a1a5c771-d06c-4f42-a40c-2a0c6db81cba">Hidradenitis suppurativa</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hidradenitis suppurativa (off-label use): Oral:</b> 100 mg once or twice daily for ≥3 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33660281','lexi-content-ref-33094412','lexi-content-ref-31237104']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33660281','lexi-content-ref-33094412','lexi-content-ref-31237104'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0676402d-6bcc-48b1-a3ce-53f79c692b71">Lyme disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Lyme disease (<i>Borrelia</i> spp. infection) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Prophylaxis:</i>
<b>Oral:</b> 200 mg as a single dose. <b>Note:</b> Prophylaxis is used only in patients who meet <b>all</b> of the following criteria: <i>Ixodes</i> spp. tick attached for ≥36 hours, prophylaxis can be given within 72 hours of tick removal, and local rate of <i>Ixodes</i> spp. tick infection with <i>Borrelia burgdorferi</i> is ≥20% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33251700']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33251700'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Treatment, erythema migrans</i>
<i>:</i>
<b>Oral:</b> 100 mg twice daily for 10 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9233865','lexi-content-ref-33251700','lexi-content-ref-12729423']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9233865','lexi-content-ref-33251700','lexi-content-ref-12729423'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Treatment, acute neurologic disease (isolated facial nerve palsy, meningitis, or radiculoneuropathy): </i>
<b>Oral:</b> 100 mg twice daily for 14 to 21 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33251700']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33251700'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Treatment, carditis (initial therapy for mild disease [first-degree atrioventricular block with PR interval &lt;300 msec] or step-down therapy after initial parenteral treatment for more severe disease once PR interval &lt;300 msec):</i>
<b>Oral:</b> 100 mg twice daily for 14 to 21 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33251700']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33251700'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Treatment, arthritis without neurologic involvement</i>: <b>Oral:</b> 100 mg twice daily for 28 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33251700']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33251700'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0acddc60-f298-46aa-ab90-6ccb55be7fd5">Malaria</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Malaria:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Prophylaxis</i>: <b>Oral</b> (immediate release and delayed release): 100 mg daily; initiate 1 to 2 days prior to travel to endemic area; continue daily during travel and for 4 weeks after leaving endemic area.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Treatment (alternative agent) (off-label use):</i>
<b>Oral:</b> 100 mg twice daily for 7 days, as part of an appropriate combination regimen. <b>Note:</b> If used for <i>P. vivax</i> or <i>P. ovale</i>, use this regimen in combination with primaquine. If used for severe malaria (after completion of IV therapy), use full 7-day schedule of doxycycline (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-CDC.2020','lexi-content-ref-WHO.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-CDC.2020','lexi-content-ref-WHO.2020'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a96b8104-65d0-48ba-b460-4308464e6db6">Otitis media, acute</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Otitis media, acute (alternative agent if unable to tolerate penicillins and cephalosporins) (off-label use):</b>
<b>Oral:</b> 100 mg every 12 hours; duration of therapy is 5 to 7 days (mild to moderate infection) <b>or</b> 10 days (severe infection) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Limb.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Limb.2019'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="61dc4516-3280-419e-a0fd-0e93be129181">Periodontitis, severe, plaque-associated</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Periodontitis, severe, plaque-associated:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For anti-collagenolytic activity following acute treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27009489']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27009489'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Subantimicrobial dosing: </i>
<b>Oral: </b>Immediate release: 20 mg twice daily for 3 to 9 months; use in addition to periodontal debridement (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26113100']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26113100'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2d4cf660-fc6c-4182-9e8b-10ee80fcb30b">Plague</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Plague <i>(Yersinia pestis</i>):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Consult public health officials for event-specific recommendations.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Postexposure prophylaxis: </i>
<b>Oral: </b>100 mg every 12 hours for 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34264565']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34264565'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Treatment of bubonic, pharyngeal, pneumonic, or septicemic plague (alternative agent for pneumonic or septicemic plague):</i>
<b>Oral, IV:</b> 200 mg initially, then 100 mg every 12 hours for 10 to 14 days and for at least a few days after clinical resolution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34264565','lexi-content-ref-Sexton.2019a']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34264565','lexi-content-ref-Sexton.2019a'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Patients who are pregnant <i>(alternative agent):</i>
<b>Oral, IV:</b> 200 mg IV initially, then 100 mg orally or IV every 12 hours <b>or</b> 200 mg IV every 24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34264565']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34264565'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ec41e633-0f0e-4d40-8f3f-14cb056b6fe6">Pleurodesis, chemical</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pleurodesis, chemical (sclerosing agent for pleural effusion) (off-label use): Intrapleural:</b> 500 mg as a single dose in 30 to 100 mL NS (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17873181','lexi-content-ref-16404570','lexi-content-ref-8494419']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17873181','lexi-content-ref-16404570','lexi-content-ref-8494419'])">Ref</a></span>). Some experts combine with or administer following instillation of a local anesthetic (eg, lidocaine, 10 to 25 mL [100 to 250 mg] of 1% solution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8494419','lexi-content-ref-3342661']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8494419','lexi-content-ref-3342661'])">Ref</a></span>) or mepivacaine 20 mL [400 mg] of 2% solution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16404570']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16404570'])">Ref</a></span>)).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="91decb71-4261-47ad-a183-3589adc0000a">Pneumonia, community-acquired, empiric therapy</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pneumonia, community-acquired, empiric therapy:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Outpatients with no risk factors for antibiotic resistant pathogens:</i>
<b>Oral:</b> 100 mg twice daily; must be used as part of an appropriate combination regimen in outpatients with comorbidities (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31573350']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31573350'])">Ref</a></span>). Some experts prefer to use as part of an appropriate combination regimen in all outpatients, regardless of comorbidities (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-File.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-File.2019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Inpatients (alternative agent):</i>
<b>Oral, IV:</b> 100 mg twice daily as part of an appropriate combination regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31573350']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31573350'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Duration: Minimum of 5 days; patients should be clinically stable with normal vital signs before discontinuing therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31573350']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31573350'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9d1b4c51-5035-4766-b50d-dd4e58990353">Prosthetic joint infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Prosthetic joint infection (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Treatment: Oral continuation therapy for S. aureus (following pathogen-specific IV therapy in patients undergoing 1-stage exchange or debridement with retention of prosthesis) (alternative agent): </i>
<b>Oral:</b> 100 mg twice daily in combination with rifampin; total duration is a minimum of 3 months, depending on patient-specific factors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Berbari.2019','lexi-content-ref-23223583']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Berbari.2019','lexi-content-ref-23223583'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Chronic suppression for staphylococci (methicillin resistant) and Cutibacterium acnes (alternative agent for C. acnes)</i>: <b>Oral:</b> 100 mg twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23223583']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23223583'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ee55d874-2d0b-4f70-bab7-3457c401ca26">Q fever</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Q fever (<i>C. burnetii</i>)</b>
<b>:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Acute symptomatic infection:</i>
<b>Note:</b> Treatment is most effective if given within the first 3 days of symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23535757']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23535757'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> 100 mg every 12 hours for 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23535757']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23535757'])">Ref</a></span>). <b>Note:</b> Some experts use in combination with hydroxychloroquine for 12 months in select patients (eg, those with acute Q fever and preexisting valvulopathy) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23794723']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23794723'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Chronic infection (eg, endocarditis, osteoarticular infection, vascular infection):</i>
<b>Oral:</b> 100 mg every 12 hours in combination with hydroxychloroquine. Duration is 18 to 24 months for endocarditis or vascular infection and 12 months in patients who are postpartum with serologic profile consistent with chronic Q fever (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23535757']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23535757'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1437b55a-5145-4c15-bba4-c28709c37109">Rhinosinusitis, acute bacterial</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Rhinosinusitis, acute bacterial (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> In uncomplicated acute bacterial rhinosinusitis, initial observation and symptom management without antibiotic therapy is appropriate in most patients. Reserve antibiotic therapy for poor follow-up or lack of improvement over the observation period (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25832968','lexi-content-ref-26785402']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25832968','lexi-content-ref-26785402'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 200 mg/day in 1 to 2 divided doses for 5 to 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22438350']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22438350'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="887b8eed-8932-4578-993c-f38dd0d1db55">Rocky Mountain spotted fever</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Rocky Mountain spotted fever:</b>
<b>Oral, IV:</b> 100 mg twice daily for 5 to 7 days or for at least 3 days after fever subsides, whichever is longer; initiate treatment as soon as possible. Severe or complicated disease may require longer treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27172113']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27172113'])">Ref</a></span>). <b>Note:</b> Some experts recommend an initial loading dose of 200 mg for critically ill patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Sexton.2019b']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Sexton.2019b'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="cc3a2a3a-842f-4019-92f3-0d78d87a74b9">Rosacea</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Rosacea:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Moderate to severe or unresponsive to topical therapy:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Traditional dosing (off label): <b>Oral:</b> Initial: 50 to 100 mg twice daily for 4 to 12 weeks; may follow with a topical agent and/or subantimicrobial doxycycline dosing for long-term management. Alternatively, may initiate therapy with subantimicrobial dosing (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18289334','lexi-content-ref-Maier.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18289334','lexi-content-ref-Maier.2019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Subantimicrobial dosing: <b>Oral: </b>40 mg once daily (delayed release; Oracea) or 20 mg twice daily (immediate release) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16243127']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16243127'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Papulopustular lesions, breakthrough flares:</i>
<b>Oral:</b> 100 mg twice daily for 10 days; continue topical maintenance therapy during and after oral treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33282106','lexi-content-ref-Maier.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33282106','lexi-content-ref-Maier.2019'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8597b7bf-d38b-46ed-ae30-27103563bc5c">Sexually transmitted infections</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Sexually transmitted infections:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Cervical infection, empiric therapy for cervicitis or pathogen-directed therapy for Chlamydia trachomatis: </i>
<b>Oral:</b> 100 mg twice daily for 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>) <b>or</b> 200 mg delayed release once daily for 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22431798']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22431798'])">Ref</a></span>); for empiric therapy, give in combination with ceftriaxone if the patient is at high risk for gonorrhea, if follow up is a concern, or if local prevalence of gonorrhea is elevated (&gt;5%) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926','lexi-content-ref-Powell.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926','lexi-content-ref-Powell.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Empiric treatment following sexual assault (off-label use):</i>
<b>Oral:</b> 100 mg twice daily for 7 days, as part of an appropriate combination regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Epididymitis, acute (off-label use): Empiric therapy for chlamydia and gonorrhea:</i>
<b>Oral:</b> 100 mg twice daily for 10 days with single dose of ceftriaxone.<b> Note: </b>An alternative regimen is recommended in patients who practice insertive anal sex (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Granuloma inguinale </i>(donovanosis) (alternative agent): <b>Oral:</b> 100 mg twice daily for &gt;3 weeks and until resolution of lesions. <b>Note:</b> If symptoms do not improve within the first few days of therapy, addition of a second agent may be considered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Lymphogranuloma venereum</i>: <b>Oral:</b> 100 mg twice daily for 21 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Pelvic inflammatory disease (off-label use):</i></p>
<p style="text-indent:-2em;margin-left:6em;">Mild to moderate pelvic inflammatory disease, outpatient therapy: <b>Oral:</b> 100 mg every 12 hours for 14 days as part of an appropriate combination regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Severe pelvic inflammatory disease, inpatient therapy: <b>Oral, IV:</b> 100 mg every 12 hours as part of an appropriate combination regimen; transition to oral therapy after 24 to 48 hours of sustained clinical improvement to complete a 14-day total course (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Postexposure prophylaxis, bacterial infections (off-label use):</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Reserve use for selected men or transgender women who have sex with men and are at high risk for bacterial sexually transmitted infections. Long-term effects on bacterial resistance are unknown (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37018493','lexi-content-ref-29229440']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37018493','lexi-content-ref-29229440'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral (immediate release and delayed release):</b> 200 mg as a single dose; administer within 24 hours but no later than 72 hours after condomless sex (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37018493','lexi-content-ref-29229440']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37018493','lexi-content-ref-29229440'])">Ref</a></span>). Maximum dose: 200 mg once every 24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37018493']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37018493'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Rectal infection, empiric therapy for acute proctitis or proctocolitis or pathogen-directed therapy for Chlamydia trachomatis (off-label use): </i>
<b>Oral:</b> 100 mg twice daily for 7 days; for empiric therapy, give in combination with a single dose of ceftriaxone. <b>Note:</b> Extend doxycycline duration to 21 days for presumptive therapy of lymphogranuloma venereum if patient has severe rectal symptoms (eg, bloody discharge, tenesmus, perianal ulcers or mucosal ulcers) and a positive rectal chlamydia NAAT or HIV infection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926','lexi-content-ref-Wilcox.2021']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926','lexi-content-ref-Wilcox.2021'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Syphilis (alternative agent for nonpregnant patients with penicillin allergy): </i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Limited data support use of doxycycline as an alternative to penicillin, and close serologic and clinical follow-up is warranted (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Early syphilis (primary, secondary, and early latent [&lt;1-year duration]): <b>Oral:</b> 100 mg twice daily for 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Late syphilis (late latent [&gt;1-year duration] or tertiary syphilis with normal CSF examination): <b>Note: </b>For tertiary syphilis, reserve use for patients who are unable to be desensitized to penicillin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hicks.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hicks.2022'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Oral:</b> 100 mg twice daily for 28 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34292926','lexi-content-ref-Hicks.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34292926','lexi-content-ref-Hicks.2022'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Urethral infection, empiric therapy for urethritis or pathogen-directed therapy for Chlamydia trachomatis:</i>
<b>Oral:</b> 100 mg twice daily for 7 days <b>or</b> 200 mg delayed release once daily for 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22431798']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22431798'])">Ref</a></span>); give in combination with ceftriaxone if there is microscopic evidence of gonococcal urethritis or if there is high clinical suspicion of gonococcal infection (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bachmann.1','lexi-content-ref-34292926']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bachmann.1','lexi-content-ref-34292926'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5fe294fd-4626-4e48-9579-84675accedc8">Skin and soft tissue infection</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Skin and soft tissue infection:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Abscess: </b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Systemic antibiotics may be reasonably withheld in healthy, immunocompetent patients with a single, small abscess that has been drained if they are clinically well and have no indwelling device, risk factors for endocarditis, or risk for methicillin-resistant <i>S. aureus </i>transmission (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24947530','lexi-content-ref-Spelman.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24947530','lexi-content-ref-Spelman.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> 100 mg twice daily for ≥5 days but may extend up to 14 days depending on severity and clinical response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24947530','lexi-content-ref-Spelman.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24947530','lexi-content-ref-Spelman.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Cellulitis, purulent or with risk for methicillin-resistant <i>S. aureus</i>:</b>
<b>Oral: </b>100 mg twice daily in combination with an additional agent (eg, amoxicillin, cephalexin) for coverage of beta-hemolytic streptococci. Treat for ≥5 days but may extend up to 14 days depending on severity and clinical response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24947530','lexi-content-ref-Spelman.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24947530','lexi-content-ref-Spelman.2022'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Impetigo or ecthyma if methicillin-resistant <i>S. aureus</i></b>
<b> is suspected or confirmed: Note: </b>For impetigo, reserve systemic therapy for patients with numerous lesions or in outbreak settings to decrease transmission (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24947530']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24947530'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> 100 mg twice daily for 7 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Baddour.2021c','lexi-content-ref-24947530']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Baddour.2021c','lexi-content-ref-24947530'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="22ab2cb7-13ce-4347-b3ac-2c0b642f1f99">Surgical prophylaxis, uterine evacuation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Surgical prophylaxis, uterine evacuation (induced abortion or pregnancy loss) (off-label use): Oral:</b> 200 mg as a single dose 1 hour prior to uterine aspiration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29794678']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29794678'])">Ref</a></span>); may be administered up to 12 hours before the procedure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21397086']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21397086'])">Ref</a></span>). <b>Note:</b> The optimal dosing regimen has not been established; various protocols are in use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21397086','lexi-content-ref-RCOG.2015','lexi-content-ref-29665357','lexi-content-ref-30125557']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21397086','lexi-content-ref-RCOG.2015','lexi-content-ref-29665357','lexi-content-ref-30125557'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bf64d97c-215c-415e-9c7b-86a9dd06850a">Tularemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Tularemia (<i>Francisella tularensis</i>):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Treatment (mild infection) (alternative agent):</i>
<b>Oral:</b> 100 mg twice daily for 14 to 21 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15677845','lexi-content-ref-24947530','lexi-content-ref-30191155']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15677845','lexi-content-ref-24947530','lexi-content-ref-30191155'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Postexposure prophylaxis (nonbioterrorism event, high-risk exposure):</i>
<b>Oral:</b> 100 mg twice daily for 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15677845']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15677845'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Bioterrorism event:</i>
<b>Note:</b> Consult public health officials for event-specific recommendations.</p>
<p style="text-indent:-2em;margin-left:6em;">Mass casualty management or postexposure prophylaxis (when used as a biological weapon): <b>Oral:</b> 100 mg twice daily for 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11386933']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11386933'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Contained casualty management (when used as a biological weapon): <b>IV</b> (may transition to oral if clinically appropriate): 100 mg every 12 hours for 14 to 21 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11386933']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11386933'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990604"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">IV, Oral:</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Mild to severe impairment:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-4767570','lexi-content-ref-4564509']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-4767570','lexi-content-ref-4564509'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Poorly dialyzed (0% to 5%); no supplemental dose or dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-6626415','lexi-content-ref-4564509','lexi-content-ref-4584946']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-6626415','lexi-content-ref-4564509','lexi-content-ref-4584946'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Poorly dialyzed; no dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-4584946']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-4584946'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19397464']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19397464'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT</b> (eg, sustained, low-efficiency diafiltration): No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50987616"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block arsc drugH1Div" id="F55158085"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Bone growth suppression</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Bone growth suppression, as evidenced by <b>growth retardation</b> (fibula), has been reported in premature infants treated with tetracycline; growth restriction up to 40% has been associated with oral tetracycline therapy but is reversible when short-term treatment is discontinued. Upon discontinuation of tetracycline, rapid compensatory bone growth is observed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Cohlan.1963','lexi-content-ref-26680308','lexi-content-ref-30442509']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Cohlan.1963','lexi-content-ref-26680308','lexi-content-ref-30442509'])">Ref</a></span>). There are limited/no data with doxycycline; therefore, the risk for bone growth suppression is extrapolated from data with tetracycline.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; tetracycline binds to calcium in growing bones and negatively affects calcium orthophosphate metabolism (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Cohlan.1963','lexi-content-ref-26680308']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Cohlan.1963','lexi-content-ref-26680308'])">Ref</a></span>); doxycycline appears to bind to calcium less than tetracycline (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30442509']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30442509'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Intermediate; deposition of tetracycline in bone has been shown after one dose and treatment with tetracycline for 9 to 12 days has resulted in restricted bone growth (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Cohlan.1963']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Cohlan.1963'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors: </i></p>
<p style="text-indent:-2em;margin-left:6em;">• Dose; tetracycline 25 mg/kg/dose every 6 hours in premature infants (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Cohlan.1963']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Cohlan.1963'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Age: Premature infants (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Cohlan.1963']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Cohlan.1963'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Esophageal injury</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Esophagitis</b>, <b>esophageal ulcer</b>, and/or <b>esophageal stenosis</b> may occur; patients with sudden onset of chest pain, dysphagia, odynophagia, and/or retrosternal pain may require assessment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31290206']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31290206'])">Ref</a></span>). Esophagitis is more frequent with doxycycline than minocycline (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22283782']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22283782'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Local caustic injury due to direct local contact as doxycycline has a pH &lt;3 (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31290206']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31290206'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; 3 to 12 days after initiation. In treatment of chronic conditions such as acne vulgaris, it can occur any time during treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31290206','lexi-content-ref-31709872']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31290206','lexi-content-ref-31709872'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors: </i></p>
<p style="text-indent:-2em;margin-left:6em;">• Administration at bedtime or prior to lying down (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31709872']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31709872'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Altered esophageal anatomy or underlying esophageal strictures</p>
<p style="text-indent:-2em;margin-left:6em;">• Inadequate fluid intake with administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31709872']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31709872'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting esophageal disorders (eg, gastroesophageal reflux disease)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Photosensitivity</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Doxycycline may cause <b>skin photosensitivity</b> reactions ranging from mild sunburn-like reactions to photodermatitis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30888626','lexi-content-ref-28291967','lexi-content-ref-22283782']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30888626','lexi-content-ref-28291967','lexi-content-ref-22283782'])">Ref</a></span>). Phototoxic reactions are restricted to exposed skin, usually develop shortly after sun exposure and appear to be dose-related (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8252763','lexi-content-ref-9382560']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8252763','lexi-content-ref-9382560'])">Ref</a></span>). Photo-<b>onycholysis </b>has also been reported with tetracyclines (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-14711147','lexi-content-ref-263881','lexi-content-ref-24015834']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-14711147','lexi-content-ref-263881','lexi-content-ref-24015834'])">Ref</a></span>). The main wavelength causing doxycycline’s phototoxic reactions is UVA1 (340-400 nm) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30888626']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30888626'])">Ref</a></span>). Chronic tetracycline use (&gt;2 months) may increase the risk of basal cell carcinoma by 11% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29073637']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29073637'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Doxycycline is activated by the radiation in the long UVA1 spectrum (340-400 nm), increasing sensitivity to sunlight (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30888626','lexi-content-ref-28291967']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30888626','lexi-content-ref-28291967'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Photosensitivity: Occurs &lt;24 hours after sun exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30888626']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30888626'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors: </i></p>
<p style="text-indent:-2em;margin-left:6em;">• Children even at very low doses (20 mg daily) may have increased susceptibility (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28291967']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28291967'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Fitzpatrick skin types I and II (white, always burns, never tans or tans minimally) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28291967']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28291967'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28291967','lexi-content-ref-8252763']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28291967','lexi-content-ref-8252763'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Lack of adherence to suggested sun avoidance, sun-protective clothing, and broad- spectrum sunscreen (UVA and UVB) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28291967']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28291967'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Living in a country with high solar radiation; even low doses can precipitate a reaction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28291967']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28291967'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Use of sunscreens with primary UVA protection offered by oxybenzone (absorbs shorter UVA radiation) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28291967']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28291967'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Skin hyperpigmentation/dental discoloration</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Doxycycline may induce diffuse <b>skin hyperpigmentation</b> (brown, bluish-grey, black discoloration) including nails, skin of hands, arms, legs, dorsal side of feet, interdigital areas, or around scars. Risk of dental staining (<b>staining of tooth</b>) and <b>enamel hypoplasia</b> with doxycycline during tooth development is controversial; however, studies have not validated these issues and most recommend short-term use (&lt;21 days) in children regardless of age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27172113','lexi-content-ref-9613662','lexi-content-ref-Poyhonen.2017','lexi-content-ref-AAP.2018','lexi-content-ref-31280586','lexi-content-ref-25794784','lexi-content-ref-30442509']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27172113','lexi-content-ref-9613662','lexi-content-ref-Poyhonen.2017','lexi-content-ref-AAP.2018','lexi-content-ref-31280586','lexi-content-ref-25794784','lexi-content-ref-30442509'])">Ref</a></span>). Local pain with the change in pigment has been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16148859']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16148859'])">Ref</a></span>). Many patients were receiving doxycycline at higher doses for prolonged periods of time as in treatment of Q fever. For treatment of Q fever, doxycycline is administered concurrently with hydroxychloroquine, which also may cause skin hyperpigmentation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26219940']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26219940'])">Ref</a></span>). Hyperpigmentation may be more prevalent with minocycline than doxycycline and associated with a greater variety of tissues (eg, bone, conjunctiva and sclera, ear tympanic membrane, internal organs, nails, subcutaneous fat, teeth and oral mucosa, and thyroid) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20720371','lexi-content-ref-11896769','lexi-content-ref-27870777','lexi-content-ref-23887527','lexi-content-ref-8436641','lexi-content-ref-32839167','lexi-content-ref-34348742']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20720371','lexi-content-ref-11896769','lexi-content-ref-27870777','lexi-content-ref-23887527','lexi-content-ref-8436641','lexi-content-ref-32839167','lexi-content-ref-34348742'])">Ref</a></span>). Partially reversible or reversible within 1 to 12 months of discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16148859','lexi-content-ref-26219940']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16148859','lexi-content-ref-26219940'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose- and time-related; doxycycline may mineralize tissue as it binds to calcium/iron to form a tetracycline-calcium/iron orthophosphate complex and/or activate melanocytes in the upper dermis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16148859','lexi-content-ref-26219940']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16148859','lexi-content-ref-26219940'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; 2 weeks to 37 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16148859','lexi-content-ref-26219940']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16148859','lexi-content-ref-26219940'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26219940']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26219940'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Long-term use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26219940']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26219940'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Pediatric: Treatment course &gt;21 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-AAP.2018','lexi-content-ref-31280586']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-AAP.2018','lexi-content-ref-31280586'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F163295"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Increased lactate dehydrogenase (2%), increased serum glucose (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distention (1%), abdominal pain (1%), diarrhea (5%), upper abdominal pain (2%), xerostomia (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Vulvovaginal candidiasis</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Basal cell carcinoma of skin (chronic use) (Li 2018), erythema multiforme (Shapiro 1997), erythematous rash, exfoliative dermatitis, maculopapular rash, onycholysis (photo-onycholysis skin hyperpigmentation; chronic use) (Dowlati 2015), skin hyperpigmentation (Akcam 2005; Keijmel 2015), skin photosensitivity (Goetze 2017; Lebrun 2012; Shapiro 1997), Stevens-Johnson syndrome (Cac 2007; Shapiro 1997), urticaria (Shapiro 1997)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Growth retardation (fibula; based on tetracycline data) (Cohlan 1963)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Anorexia, <i>Clostridioides difficile</i>-associated diarrhea (not associated with increased risk) (Deshpanda 2013; Tariq 2018), enamel hypoplasia (Stultz 2019), enterocolitis, esophageal stenosis (Bonavina 1989), esophageal ulcer (Guo 2019), esophagitis (Kim 2014), glossitis, nausea (Shapiro 1997), staining of tooth (Stultz 2019), vomiting (Shapiro 1997)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatotoxicity (including hepatic coma, hepatic failure, hepatic necrosis, toxic hepatitis) (Björnsson 1997; Heaton 2007)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Angioedema (Shapiro 1997), drug reaction with eosinophilia and systemic symptoms (Lebrun-Vignes 2012), hypersensitivity reaction (Shapiro 1997), nonimmune anaphylaxis (Raeder 1984), serum sickness (Shapiro 1997)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Bulging fontanel (based on tetracycline data) (Fields 1961; Opfer 1963), intracranial hypertension (causality not established; females of childbearing age who are overweight or have a history of intracranial hypertension may be at greater risk)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Exacerbation of systemic lupus erythematosus</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased blood urea nitrogen</p></div>
<div class="block coi drugH1Div" id="F163310"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to doxycycline, other tetracyclines, or any component of the formulation.</p>
<p style="text-indent:-2em;margin-left:2em;">Doxytab, JAMP-doxycycline [Canadian products]: Additional contraindications: Myasthenia gravis; concurrent use with isotretinoin.</p>
<p style="text-indent:-2em;margin-left:2em;">Periostat, Apprilon [Canadian products]: Additional contraindications: Use in infants and children &lt;8 years of age or during second or third trimester of pregnancy; breast-feeding.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block war drugH1Div" id="F163292"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Increased BUN: May be associated with increases in BUN secondary to antianabolic effects; this does not occur with use of doxycycline in patients with renal impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Intracranial hypertension: Intracranial hypertension (pseudotumor cerebri) has been reported; headache, blurred vision, diplopia, vision loss, and/or papilledema may occur. Women of childbearing age who are overweight or have a history of intracranial hypertension are at greater risk. Intracranial hypertension typically resolves after discontinuation of treatment; however, permanent visual loss is possible. If visual symptoms develop during treatment, prompt ophthalmologic evaluation is warranted. Intracranial pressure can remain elevated for weeks after drug discontinuation; monitor patient until stable.</p>
<p style="text-indent:-2em;margin-left:4em;">• Superinfection: Prolonged use may result in fungal or bacterial superinfection.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Oral candidiasis: Safety and effectiveness have not been established for treatment of periodontitis in patients with coexistent oral candidiasis; use with caution in patients with a history or predisposition to oral candidiasis.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Neonatal: Preterm neonates receiving oral tetracycline experienced a reversible decrease in fibular growth rate; data with doxycycline are unavailable; use caution (Cohlan 1963; manufacturer's labeling).</p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: Due to risks of permanent tooth staining, manufacturers generally recommend to use tetracycline antibiotics in patients &lt;8 years of age only when benefits outweigh the risks; however, studies have not validated the concern for tooth staining with short-term use of doxycycline (&lt;21 days) and short-term use is considered acceptable in children regardless of age (CDC [Biggs 2016]; Lochary 1998; Pöyhönen 2017; <i>Red Book</i> [AAP 2021]; Stultz 2019; Todd 2015; Wormser 2019).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Oracea, Apprilon [Canadian product]: Should not be used for the treatment or prophylaxis of bacterial infections because the lower dose of drug per capsule may be subefficacious and promote resistance.</p>
<p style="text-indent:-2em;margin-left:4em;">• Sulfite sensitivity: Syrup may contain sodium metabisulfite, which may cause allergic reactions in certain individuals (eg, asthmatic patients).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Acne: The American Academy of Dermatology acne guidelines recommend doxycycline as adjunctive treatment for moderate and severe acne and forms of inflammatory acne that are resistant to topical treatments. Concomitant topical therapy with benzoyl peroxide or a retinoid should be administered with systemic antibiotic therapy (eg, doxycycline) and continued for maintenance after the antibiotic course is completed (AAD [Zaenglein 2016]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Limitations of use: Malaria prophylaxis: Doxycycline does not completely suppress asexual blood stages of <i>Plasmodium</i> strains; does not suppress <i>P. falciparum's</i> sexual blood stage gametocytes. Patients completing a regimen may still transmit the infection to mosquitoes outside endemic areas.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878434"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Some dosage forms may contain propylene glycol; in neonates, large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Shehab 2009).</p></div>
<div class="block dosfc drugH1Div" id="F23449398"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Morgidox kits contain doxycycline capsules 100 mg, plus AcuWash moisturizing Daily Cleanser</p>
<p style="text-indent:-2em;margin-left:2em;">NizAzel Doxy kits contain doxycycline tablets 100 mg, plus NicAzel FORTE dietary supplement tablets</p></div>
<div class="block foc drugH1Div" id="F163303"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral, as hyclate [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Morgidox: 100 mg [DSC] [contains fd&amp;c blue #1 (brilliant blue)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Vibramycin: 100 mg [contains fd&amp;c blue #1 (brilliant blue)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mg, 100 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral, as monohydrate [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Mondoxyne NL: 75 mg [DSC], 100 mg [contains quinoline yellow (d&amp;c yellow #10)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Okebo: 75 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mg, 75 mg, 100 mg, 150 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule Delayed Release, Oral, as monohydrate [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Oracea: 40 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 40 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Kit, Combination, as hyclate [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Morgidox: 1 x 100 mg [DSC], 2 x 100 mg [DSC] [contains cetyl alcohol, edetate (edta) disodium, fd&amp;c blue #1 (brilliant blue)]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous, as hyclate [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous, as hyclate [strength expressed as base, preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Doxy 100: 100 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg (1 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension Reconstituted, Oral, as monohydrate [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Vibramycin: 25 mg/5 mL (60 mL) [contains fd&amp;c blue #1 (brilliant blue), methylparaben, propylparaben; raspberry flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 25 mg/5 mL (60 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Syrup, Oral, as calcium [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Vibramycin: 50 mg/5 mL (473 mL [DSC]) [contains butylparaben, propylene glycol, propylparaben, sodium metabisulfite]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as hyclate [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Acticlate: 75 mg [DSC] [contains fd&amp;c blue #1 (brilliant blue), fd&amp;c yellow #6 (sunset yellow)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Acticlate: 150 mg [DSC] [scored; contains fd&amp;c blue #2 (indigotine,indigo carmine)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lymepak: 100 mg [DSC] [contains fd&amp;c blue #1 (brilliant blue), fd&amp;c yellow #6 (sunset yellow), quinoline yellow (d&amp;c yellow #10)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">TargaDOX: 50 mg [contains fd&amp;c blue #2 (indigotine,indigo carmine), fd&amp;c yellow #6 (sunset yellow)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 20 mg, 50 mg, 75 mg, 100 mg, 150 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as monohydrate [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Avidoxy: 100 mg [contains fd&amp;c yellow #6(sunset yellow)alumin lake, quinoline (d&amp;c yellow #10) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mg, 75 mg, 100 mg, 150 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Delayed Release, Oral, as hyclate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Doryx MPC: 60 mg [contains corn starch]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Delayed Release, Oral, as hyclate [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Doryx: 50 mg [contains corn starch]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Doryx: 80 mg [DSC], 200 mg [DSC] [scored; contains corn starch]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Doryx MPC: 120 mg [contains corn starch]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mg, 75 mg, 80 mg, 100 mg, 150 mg, 200 mg</p></div>
<div class="block geq drugH1Div" id="F163288"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F163312"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsule, delayed release</b> (Oracea Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg (per each): $36.56</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Doxycycline Hyclate Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $2.16 - $2.25</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $0.38 - $9.62</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Doxycycline Monohydrate Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $1.45 - $1.55</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">75 mg (per each): $16.40 - $16.92</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $2.13 - $2.56</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150 mg (per each): $24.65</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Mondoxyne NL Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $10.52</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Vibramycin Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $1.09</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Doxy 100 Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $25.20</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Doxycycline Hyclate Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $17.61 - $30.20</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension (reconstituted)</b> (Doxycycline Monohydrate Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg/5 mL (per mL): $0.38</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension (reconstituted)</b> (Vibramycin Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg/5 mL (per mL): $0.83</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, EC</b> (Doryx MPC Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">60 mg (per each): $24.00</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">120 mg (per each): $15.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, EC</b> (Doryx Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $14.22</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, EC</b> (Doxycycline Hyclate Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $11.73 - $13.51</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">75 mg (per each): $10.22</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">80 mg (per each): $39.58</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $13.15</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150 mg (per each): $17.60</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg (per each): $43.42 - $50.01</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Doxycycline Hyclate Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $0.74 - $1.30</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $13.20</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">75 mg (per each): $31.15 - $31.19</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $2.62 - $6.15</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150 mg (per each): $31.15 - $31.19</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Doxycycline Monohydrate Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $2.89 - $3.36</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">75 mg (per each): $4.93 - $4.99</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $4.23 - $4.92</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150 mg (per each): $9.14</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (TargaDOX Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $17.86</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866677"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Periostat: 20 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral, as hyclate [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule Delayed Release, Oral, as monohydrate [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Apprilon: 40 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 40 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as hyclate [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg</p></div>
<div class="block exp drugH1Div" id="F163308"><span class="drugH1">Extemporaneous Preparations</span>
<p style="text-indent:0em;display:inline">If a public health emergency is declared and liquid doxycycline is unavailable for the treatment of anthrax, emergency doses may be prepared for children or adults who cannot swallow tablets.</p>
<p style="text-indent:0em;margin-top:2em;text-align:justify;">Add 20 mL of water to one 100 mg tablet. Allow tablet to soak in the water for 5 minutes to soften. Crush into a fine powder and stir until well mixed. Appropriate dose should be taken from this mixture. To increase palatability, mix with food or drink. If mixing with drink, add 15 mL of  milk, chocolate milk, chocolate pudding, or apple juice to the appropriate dose of mixture. If using apple juice, also add 4 teaspoons of sugar. Doxycycline and water mixture may be stored at room temperature for up to 24 hours.</p>
<div class="reference">US Food and Drug Administration, Center for Drug Evaluation and Research, “Public Health Emergency Home Preparation Instructions for Doxycycline.” Available at   <a href="/external-redirect?target_url=http%3A%2F%2Fwww.fda.gov%2FDrugs%2FEmergencyPreparedness%2FBioterrorismandDrugPreparedness%2Fucm130996.htm&amp;token=eOAl4%2B1qn%2FDPeqwrJV1jWsf9KilooALKe1axTSIQvv7QK32LiEzpYsK%2BR1GUECRGXYF51VF9amZXG1D83TfPQmIuqwxO%2BY1ZFVWZjdlxoYBnc0GscrY3EmH1OOJmBqD%2F&amp;TOPIC_ID=13255" target="_blank">http://www.fda.gov/Drugs/EmergencyPreparedness/BioterrorismandDrugPreparedness/ucm130996.htm</a></div>
</div>
<div class="block admp drugH1Div" id="F52612640"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Administer capsules or tablets with adequate amounts of fluid and remain in an upright position following administration (to avoid esophageal irritation); may be administered with food or milk to decrease GI upset (though absorption may be slightly reduced). Shake suspension well before use.</p>
<p style="text-indent:-2em;margin-left:4em;">Acticlate:</p>
<p style="text-indent:-2em;margin-left:6em;">Capsule: Swallow capsule whole; do not break, open, crush, dissolve, or chew the capsule.</p>
<p style="text-indent:-2em;margin-left:6em;">Tablet (150 mg): May be broken into <sup>1</sup>/<sub>3</sub> to provide 50 mg dose or <sup>2</sup>/<sub>3</sub> to provide 100 mg/dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Doryx: May break up the tablet and sprinkle the delayed-release pellets on a spoonful of applesauce. Do <b>not</b> crush or damage the delayed-release pellets; loss or damage of pellets prevents using the dose. Swallow the Doryx/applesauce mixture immediately without chewing. Discard mixture if not used immediately.</p>
<p style="text-indent:-2em;margin-left:4em;">Doryx MPC: Do not chew or crush tablets.</p>
<p style="text-indent:-2em;margin-left:2em;">Parenteral: For IV use only; administer over 1 to 4 hours; avoid rapid infusion. Avoid extravasation (may be an irritant). Duration of IV therapy should be minimized, when possible, to avoid risk of thrombophlebitis.</p></div>
<div class="block adm drugH1Div" id="F163306"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Oral administration is preferable unless patient has significant nausea and vomiting; IV and oral routes are bioequivalent.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> In general, administer with meals to decrease GI upset; however, some manufacturer labeling recommends administration on an empty stomach (see below). Administer capsules and tablets with at least 8 ounces (240 mL) of water and have patient sit up for at least 30 minutes or 1 to 2 hours (Canadian labeling) after taking to reduce the risk of esophageal irritation and ulceration.</p>
<p style="text-indent:-2em;margin-left:4em;">Acticlate: Swallow capsule whole; do not break, open, crush, dissolve, or chew. The 150 mg tablet may be broken into 2/3 or 1/3 to provide a 100 mg and 50 mg strength, respectively.</p>
<p style="text-indent:-2em;margin-left:4em;">Doxycycline 20 mg tablet, Oracea, Apprilon [Canadian product]: Administer on an empty stomach 1 hour before or 2 hours after meals.</p>
<p style="text-indent:-2em;margin-left:4em;">Doryx: Do not chew or crush tablets. May be administered by carefully breaking up the tablet and sprinkling tablet contents on a spoonful of cold applesauce; applesauce should be soft enough to swallow without chewing. The delayed-release pellets must not be crushed or damaged when breaking up tablet. Should be administered immediately after preparation and without chewing; follow with a cool 8-ounce (240 mL) glass of water to ensure complete swallowing. If applesauce/pellet mixture is not administered immediately, discard (do not store for future use).</p>
<p style="text-indent:-2em;margin-left:4em;">Doryx MPC: Do not chew or crush tablets.</p>
<p style="text-indent:-2em;margin-left:4em;">JAMP-doxycycline [Canadian product]: Administer with a full glass of water and with or after a meal to minimize GI upset; patient should not lay down after administration and should not go to bed within 1 to 2 hours of administration.</p>
<p style="text-indent:-2em;margin-left:4em;">Periostat [Canadian product]: Administer 1 hour before breakfast and evening meal.</p>
<p style="text-indent:-2em;margin-left:4em;">Bariatric surgery: Some institutions may have specific protocols that conflict with these recommendations; refer to institutional protocols as appropriate.</p>
<p style="text-indent:-2em;margin-left:6em;">Capsule, delayed release: Delayed-release capsule may not be opened. Switch to IR formulation (capsule, tablet, or oral suspension) at closest possible dose.</p>
<p style="text-indent:-2em;margin-left:6em;">Tablet, extended release: Delayed-release tablet can be cut into small pieces but not crushed.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV</b>
<b>:</b> For IV use only. Infuse slowly, usually over 1 to 4 hours. Avoid extravasation (may be an irritant). Duration of IV therapy should be minimized, when possible, to avoid risk of thrombophlebitis. IV and oral routes are bioequivalent.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Intrapleural (off-label route):</b> Instill diluted doxycycline (combined with or following instillation of a local anesthetic) into chest tube; clamp chest tube for 2 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16404570','lexi-content-ref-8494419']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16404570','lexi-content-ref-8494419'])">Ref</a></span>).</p></div>
<div class="block sts drugH1Div" id="F163323"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Capsule, tablet, delayed-release tablet: Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F). Protect from light and moisture.</p>
<p style="text-indent:-2em;margin-left:2em;">Syrup, oral suspension: Store below 30°C (86°F); protect from light.</p>
<p style="text-indent:-2em;margin-left:2em;">Injection: Store intact vials at 20°C to 25°C (68°F to 77°F); protect from light. Stability of IV infusion varies based on solution; refer to manufacturer's labeling.</p></div>
<div class="block usep drugH1Div" id="F53566592"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of infections caused by susceptible <i>Rickettsia</i> including Rocky Mountain spotted fever; treatment of sexually transmitted infections caused by susceptible <i>Chlamydia</i>, <i>Ureaplasma</i>, <i>Klebsiella</i>, <i>Neisseria</i>, and <i>Haemophilus</i> species; treatment of respiratory tract infections caused by susceptible <i>Mycoplasma</i>, <i>Chlamydophila</i>, <i>Haemophilus</i>, <i>Klebsiella</i>, and <i>Streptococcus</i> species; treatment of infections caused by susceptible gram-negative and gram-positive organisms including <i>Borrelia</i>, <i>Ureaplasma</i>, <i>Haemophilus</i>, <i>Yersinia</i>, <i>Francisella</i>, <i>Vibrio</i>, <i>Campylobacter</i>, <i>Brucella</i>, <i>Bartonella</i>, <i>Calymmatobacterium</i>, <i>Escherichia</i>, <i>Enterobacter</i>, <i>Shigella</i>, <i>Acinetobacter</i>, and <i>Klebsiella</i> species; treatment of ophthalmic infections caused by susceptible <i>Chlamydia</i> species; treatment of anthrax (<i>Bacillus anthracis</i>); treatment of plague (<i>Yersinia pestis</i>); treatment of cholera (<i>Vibrio cholerae</i>); treatment of brucellosis in combination with streptomycin; alternative treatment for infections caused by susceptible bacteria when penicillin is contraindicated including <i>Treponema</i> (eg, syphilis), <i>Listeria</i>, <i>Fusobacterium</i>, <i>Actinomyces</i>, and <i>Clostridium</i> species; adjunctive treatment for acute intestinal amebiasis and severe acne; alternative for malaria prophylaxis in travelers to areas with resistant strains (All indications: FDA approved in ages ≥8 years and adults and in patients &lt;8 years in severe or life-threatening illness); treatment of inflammatory lesions (papules and pustules) associated with rosacea (Oracea: FDA approved in adults). Has also been used for community-acquired methicillin-resistant <i>Staphylococcus aureus</i> cellulitis and ehrlichiosis.</p></div>
<div class="block mst drugH1Div" id="F163372"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Doxycycline may be confused with dicyclomine, doxepin, doxylamine</p>
<p style="text-indent:-2em;margin-left:4em;">Doxy100 may be confused with Doxil</p>
<p style="text-indent:-2em;margin-left:4em;">Monodox may be confused with Maalox</p>
<p style="text-indent:-2em;margin-left:4em;">Oracea may be confused with Orencia</p>
<p style="text-indent:-2em;margin-left:4em;">Vibramycin may be confused with vancomycin, Vibativ</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Oracea (US brand name) is marketed in Canada under the brand name Apprilon</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F163358"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F163297"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Aminolevulinic Acid (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminolevulinic Acid (Topical): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Topical). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antacids: May decrease the absorption of Tetracyclines. Management: Separate administration of antacids and oral tetracycline derivatives by several hours when possible to minimize the extent of this potential interaction. Monitor for decreased therapeutic effects of tetracyclines.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bacillus clausii: Antibiotics may diminish the therapeutic effect of Bacillus clausii.  Management: Bacillus clausii should be taken in between antibiotic doses during concomitant therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Barbiturates: May decrease the serum concentration of Doxycycline.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bile Acid Sequestrants: May decrease the absorption of Tetracyclines.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bismuth Subcitrate: May decrease the serum concentration of Tetracyclines. Management: Avoid administration of oral tetracyclines within 30 minutes of bismuth subcitrate administration.  This is of questionable significance for at least some regimens intended to treat H. pylori infections.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bismuth Subsalicylate: May decrease the serum concentration of Tetracyclines. Management: Consider dosing tetracyclines 2 hours before or 6 hours after bismuth. The need to separate doses during Helicobacter pylori eradication regimens is questionable.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Calcium Salts: May decrease the serum concentration of Tetracyclines. Management: If coadministration of oral calcium with oral tetracyclines cannot be avoided, consider separating administration of each agent by several hours.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CarBAMazepine: May decrease the serum concentration of Doxycycline.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine.  Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Oral): May diminish the therapeutic effect of Antibiotics.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fecal Microbiota (Live) (Rectal): Antibiotics may diminish the therapeutic effect of Fecal Microbiota (Live) (Rectal). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosphenytoin: May decrease the serum concentration of Doxycycline.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Antibiotics may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inhibitors of the Proton Pump (PPIs and PCABs): May decrease the bioavailability of Doxycycline.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iron Preparations: Tetracyclines may decrease the absorption of Iron Preparations. Iron Preparations may decrease the serum concentration of Tetracyclines.  Management: Avoid this combination if possible. Administer oral iron preparations at least 2 hours before, or 4 hours after, the dose of the oral tetracycline derivative. Monitor for decreased therapeutic effect of oral tetracycline derivatives.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lanthanum: May decrease the serum concentration of Tetracyclines. Management: Administer oral tetracycline antibiotics at least 2 hours before or after lanthanum.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lithium: Tetracyclines may increase the serum concentration of Lithium. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Magnesium Dimecrotate: May interact via an unknown mechanism with Tetracyclines.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Magnesium Salts: May decrease the absorption of Tetracyclines. Only applicable to oral preparations of each agent. Management: Avoid coadministration of oral magnesium salts and oral tetracyclines. If coadministration cannot be avoided, administer oral magnesium at least 2 hours before, or 4 hours after, oral tetracyclines. Monitor for decreased tetracycline therapeutic effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mecamylamine: Tetracyclines may enhance the neuromuscular-blocking effect of Mecamylamine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methoxsalen (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Methoxsalen (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methoxyflurane: Tetracyclines may enhance the nephrotoxic effect of Methoxyflurane. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mipomersen: Tetracyclines may enhance the hepatotoxic effect of Mipomersen. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Tetracyclines. Management: Avoid this combination if possible. If coadministration cannot be avoided, administer the polyvalent cation-containing multivitamin at least 2 hours before or 4 hours after the tetracycline derivative. Monitor for decreased tetracycline effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with AE, No Iron): May decrease the serum concentration of Tetracyclines. Management: If coadministration of a polyvalent cation-containing multivitamin with oral tetracyclines cannot be avoided, administer the polyvalent cation-containing multivitamin either 2 hours before or 4 hours after the tetracycline product.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular-Blocking Agents: Tetracyclines may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Penicillins: Tetracyclines may diminish the therapeutic effect of Penicillins. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phenytoin: May decrease the serum concentration of Doxycycline.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polyethylene Glycol-Electrolyte Solution: May decrease the absorption of Tetracyclines. Management: Give oral tetracyclines at least 2 hours before or at least 6 hours after polyethylene glycol-electrolyte solutions that contain magnesium sulfate (Suflave brand). Other products without magnesium do not require dose separation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinapril: May decrease the serum concentration of Tetracyclines.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Retinoic Acid Derivatives: Tetracyclines may enhance the adverse/toxic effect of Retinoic Acid Derivatives. The development of pseudotumor cerebri is of particular concern. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">RifAMPin: May decrease the serum concentration of Doxycycline.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Strontium Ranelate: May decrease the serum concentration of Tetracyclines. Management: In order to minimize any potential impact of strontium ranelate on tetracycline antibiotic concentrations, it is recommended that strontium ranelate treatment be interrupted during tetracycline therapy.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sucralfate: May decrease the absorption of Tetracyclines. Management: Administer most tetracycline derivatives at least 2 hours prior to sucralfate in order to minimize the impact of this interaction. Administer oral omadacycline 4 hours prior to sucralfate.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sucroferric Oxyhydroxide: May decrease the serum concentration of Tetracyclines. Management: Administer oral/enteral doxycycline at least 1 hour before sucroferric oxyhydroxide. Specific dose separation guidelines for other tetracyclines are not presently available. No interaction is anticipated with parenteral administration of tetracyclines.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sulfonylureas: Tetracyclines may enhance the hypoglycemic effect of Sulfonylureas. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Avoid use of live attenuated typhoid vaccine (Ty21a)  in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Verteporfin: Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Tetracyclines may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F163326"><span class="drugH1">Food Interactions</span>
<p style="text-indent:-2em;margin-left:2em;">Ethanol: Chronic ethanol ingestion may reduce the serum concentration of doxycycline.</p>
<p style="text-indent:-2em;margin-left:2em;">Food: Doxycycline serum levels may be slightly decreased if taken with high-fat meal or milk. Administration with iron or calcium may decrease doxycycline absorption. May decrease absorption of calcium, iron, magnesium, zinc, and amino acids. Management: Administer Doryx and Doryx MPC without regard to meals. Administer Oracea and doxycycline 20 mg tablet on an empty stomach 1 hour before or 2 hours after meals.</p></div>
<div class="block dic drugH1Div" id="F163314"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Tetracyclines (in general): Take with food if gastric irritation occurs. While administration with food may decrease GI absorption of doxycycline by up to 20%, administration on an empty stomach is generally not recommended due to GI intolerance. Of currently available tetracyclines, doxycycline has the least affinity for calcium.</p>
<p style="text-indent:-2em;margin-left:2em;">Doxycycline 20 mg tablet, Oracea, Apprilon [Canadian product]: Manufacturer states to take on an empty stomach 1 hour before or 2 hours after meals. Take with food if gastric irritation occurs.</p>
<p style="text-indent:-2em;margin-left:2em;">Periostat [Canadian product]: Manufacturer states to take at least 1 hour before morning and evening meals. Take with food if gastric irritation occurs.</p>
<p style="text-indent:-2em;margin-left:2em;">Some products may contain sodium.</p></div>
<div class="block pri drugH1Div" id="F163313"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Tetracyclines cross the placenta (Mylonas 2011).</p>
<p style="text-indent:0em;margin-top:2em;">Therapeutic doses of doxycycline during pregnancy are unlikely to produce substantial teratogenic risk, but data are insufficient to say that there is no risk. In general, reports of exposure have been limited to short durations of therapy in the first trimester. Tetracyclines accumulate in developing teeth and long tubular bones (Mylonas 2011). Permanent discoloration of teeth (yellow, gray, brown) can occur following in utero exposure and is more likely to occur following long-term or repeated exposure.</p>
<p style="text-indent:0em;margin-top:2em;">Doxycycline is used for the treatment of Lyme disease. Vertical transmission from mother to fetus is not well documented; it is unclear if infection increases the risk of adverse pregnancy outcomes. A single prophylactic dose of doxycycline can be used in pregnant patients; the use of treatment doses should be individualized (IDSA/AAN/ACR [Lantos 2021]; Lambert 2020; SOGC [Smith 2020]).</p>
<p style="text-indent:0em;margin-top:2em;">Doxycycline is the recommended agent for the treatment of Rocky Mountain spotted fever (RMSF) in pregnant patients (CDC [Biggs 2016]).</p>
<p style="text-indent:0em;margin-top:2em;">Untreated plague (<i>Yersinia pestis</i>) infection in pregnant patients may result in hemorrhage (including postpartum hemorrhage), maternal and fetal death, preterm birth, and stillbirth. Limited data suggest maternal-fetal transmission of <i>Y. pestis</i> can occur if not treated. Pregnant patients should be treated for <i>Y. pestis; </i>parenteral antibiotics are preferred for initial treatment when otherwise appropriate. Doxycycline may be used as an alternative antibiotic for treating pregnant patients with bubonic, pharyngeal, pneumonic, or septicemic plague. Doxycycline may also be used as an alternative antibiotic for pre- and postexposure prophylaxis in pregnant patients exposed to <i>Y. pestis </i>(CDC [Nelson 2021]).</p>
<p style="text-indent:0em;margin-top:2em;">For other indications, many guidelines consider use of doxycycline to be contraindicated during pregnancy, or to be a relative contraindication in pregnant patients if other agents are available and appropriate for use (CDC [Anderson 2013]; CDC 2023b; HHS [OI adult] 2022; IDSA [Stevens 2014]). Doxycycline should not be used for the treatment of acne or rosacea in pregnant patients (AAD [Zaenglein 2016]). When systemic antibiotics are needed for dermatologic conditions, other agents are preferred (Kong 2013; Murase 2014). As a class, tetracyclines are generally considered second-line antibiotics in pregnant patients and their use should be avoided (Mylonas 2011).</p></div>
<div class="block mopp drugH1Div" id="F53566593"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">BUN, CBC, and liver function tests with prolonged use. Changes in bowel movement frequency or consistency; thrombophlebitis with prolonged IV use.</p></div>
<div class="block pha drugH1Div" id="F163291"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:-2em;margin-left:2em;">Inhibits protein synthesis by binding with the 30S and possibly the 50S ribosomal subunit(s) of susceptible bacteria; may also cause alterations in the cytoplasmic membrane</p>
<p style="text-indent:-2em;margin-left:2em;">20 mg tablets and capsules (Periostat [Canadian product]): Proposed mechanism: Has been shown to inhibit collagenase activity in vitro. Also has been noted to reduce elevated collagenase activity in the gingival crevicular fluid of patients with periodontal disease. Systemic levels do not reach inhibitory concentrations against bacteria.</p></div>
<div class="block phk drugH1Div" id="F163309"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Oral: Almost completely absorbed from the GI tract; average peak plasma concentration may be reduced ~20% (30% for Doryx MPC) by high-fat meal or milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: Widely into body tissues and fluids including synovial, pleural, prostatic, seminal fluids, and bronchial secretions; saliva, aqueous humor, and CSF penetration is poor.</p>
<p style="text-indent:-2em;margin-left:4em;">V<sub>d</sub>: Infants, Children, and Adolescents: Median: 1.36 L/kg (range: 0.38 to 3.18 L/kg) (Thompson 2019).</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: &gt;90%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Not hepatic; partially inactivated in GI tract by chelate formation.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Reduced at high pH; may be clinically significant in patients with gastrectomy, gastric bypass surgery or who are otherwise deemed achlorhydric.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: 89.6% (Thompson 2019).</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: Median: 18.8 hours (range: 4.8 to 41.3 hours) (Thompson 2019).</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: 18 to 22 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: Oral: Immediate release: 1.5 to 4 hours; delayed release: 2.8 to 3 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Feces (30%); urine (23% to 40%).</p></div>
<div class="block phksp drugH1Div" id="F51153995"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Excretion by the kidneys may fall as low as 1% to 5% in 72 hours in patients with CrCl &lt;10 mL/minute.</p>
<p style="text-indent:-2em;margin-left:2em;">Anti-infective considerations:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Parameters associated with efficacy:</i> Time and concentration dependent, associated with 24-hour area under the curve (AUC<sub>24</sub>)/minimum inhibitory concentration (MIC); however, no specific goal AUC<sub>24</sub>/MIC has been identified (Agwuh 2006; Ambrose 2007; Cunha 2000; Smirnova 2011).</p>
<p style="text-indent:-2em;margin-left:6em;">Expected drug exposure in normal renal function: AUC: Adults: Oral: 200 mg once daily for 1 dose, then 100 mg once daily: 12.7 ± 4.9 mg•hour/L (Schreiner 1985).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Postantibiotic effect:</i> 0.7 to 2.8 hours, depending on organism (eg, <i>S. aureus</i>, <i>S. pneumoniae</i>, <i>E. coli</i>) (Cunha 2000).</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F58843208"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Doxydar | DuraDox | Farcodoxin | Monodoks | Tabocine | Unidox | Vibramycin</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-Abramowicz.2002">
<a name="Abramowicz.2002"></a>Abramowicz M. Antimicrobial Prophylaxis in Surgery. <i>Medical Letter on Drugs and Therapeutics, Handbook of Antimicrobial Therapy</i>. 16th ed. Medical Letter; 2002.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21397086">
<a name="21397086"></a>Achilles SL, Reeves MF; Society of Family Planning. Prevention of infection after induced abortion: release date October 2010: SFP guideline 20102. <i>Contraception</i>. 2011;83(4):295-309. doi:10.1016/j.contraception.2010.11.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/21397086/pubmed" id="21397086" target="_blank">21397086</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Acticlate.2020.03">
<a name="Acticlate.2020.03"></a>Acticlate (doxycycline hyclate) [prescribing information]. Malvern, PA: Almirall LLC; August 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Adoxa.2012.02">
<a name="Adoxa.2012.02"></a>Adoxa (doxycycline) [prescribing information]. Melville, NY: PharmaDerm; February 2012.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16816396">
<a name="16816396"></a>Agwuh KN, MacGowan A. Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines. <i>J Antimicrob Chemother.</i> 2006;58(2):256-265. doi:10.1093/jac/dkl224<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/16816396/pubmed" id="16816396" target="_blank">16816396</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9989538">
<a name="9989538"></a>Ailani RK, Agastya G, Ailani RK, et al. Doxycycline is a Cost-Effective Therapy for Hospitalized Patients With Community-Acquired Pneumonia. <i>Arch Intern Med.</i> 1999;159(3):266-270.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/9989538/pubmed" id="9989538" target="_blank">9989538</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16148859">
<a name="16148859"></a>Akcam M, Artan R, Akcam FZ, Yilmaz A. Nail discoloration induced by doxycycline. <i>Pediatr Infect Dis J</i>. 2005;24(9):845-846. doi:10.1097/01.inf.0000177283.71692.56<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/16148859/pubmed" id="16148859" target="_blank">16148859</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18289334">
<a name="18289334"></a>Akhyani M, Ehsani AH, Ghiasi M, Jafari AK. Comparison of efficacy of azithromycin vs. doxycycline in the treatment of rosacea: a randomized open clinical trial. <i>Int J Dermatol</i>. 2008;47(3):284-288. doi:10.1111/j.1365-4632.2008.03445.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/18289334/pubmed" id="18289334" target="_blank">18289334</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4767570">
<a name="4767570"></a>Alestig K. Studies on doxycycline during intravenous and oral treatment with reference to renal function. <i>Scand J Infect Dis</i>. 1973;5(3):193-198. doi:10.3109/inf.1973.5.issue-3.07<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/4767570/pubmed" id="4767570" target="_blank">4767570</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31290206">
<a name="31290206"></a>Al Rawahi Y, Dutt S. Doxycycline-induced oesophageal ulcer in a teenager: A case report. <i>J Paediatr Child Health</i>. 2019;55(12):1499-1500. doi:10.1111/jpc.14561<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/31290206/pubmed" id="31290206" target="_blank">31290206</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17143821">
<a name="17143821"></a>Ambrose PG, Bhavnani SM, Rubino CM, et al. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. <i>Clin Infect Dis.</i> 2007;44(1):79-86. doi:10.1086/510079<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/17143821/pubmed" id="17143821" target="_blank">17143821</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>American Academy of Pediatrics Committee on Drugs. "Inactive" ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAP.2021">
<a name="AAP.2021"></a>American Academy of Pediatrics (AAP). In: Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH, eds. <i>Red Book: 2021-2024 Report of the Committee on Infectious Diseases</i>. 32nd ed. American Academy of Pediatrics; 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-AAP.2018">
<a name="AAP.2018"></a>American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2018 Report of the Committee on Infectious Diseases</i>. 31st ed. American Academy of Pediatrics; 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23812485">
<a name="23812485"></a>American College of Obstetricians and Gynecologists (ACOG). ACOG Practice Bulletin No. 135: Second-trimester abortion. <i>Obstet Gynecol</i>. 2013;121(6):1394-1406. doi:10.1097/01.AOG.0000431056.79334.cc<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/23812485/pubmed" id="23812485" target="_blank">23812485</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29794678">
<a name="29794678"></a>American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins--Gynecology. ACOG Practice Bulletin No. 195: Prevention of infection after gynecologic procedures. <i>Obstet Gynecol</i>. 2018;131(6):e172-e1189. doi:10.1097/AOG.0000000000002670<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/29794678/pubmed" id="29794678" target="_blank">29794678</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23535757">
<a name="23535757"></a>Anderson A, Bijlmer H, Fournier PE, et al. Diagnosis and management of Q fever--United States, 2013: recommendations from CDC and the Q Fever Working Group. <i>MMWR Recomm Rep</i>. 2013;62(RR-03):1-30.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/23535757/pubmed" id="23535757" target="_blank">23535757</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1934918">
<a name="1934918"></a>Anderson PO. Drug use during breast-feeding. <i>Clin Pharm</i>. 1991;10(8):594-624.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/1934918/pubmed" id="1934918" target="_blank">1934918</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27060684">
<a name="27060684"></a>Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/27060684/pubmed" id="27060684" target="_blank">27060684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14726904">
<a name="14726904"></a>Anon JB, Jacobs MR, Poole MD, et al; Sinus And Allergy Health Partnership. Antimicrobial treatment guidelines for acute bacterial rhinosinusitis. <i>Otolaryngol Head Neck Surg</i>. 2004;130(1 suppl):1-45. doi:10.1016/j.otohns.2003.12.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/14726904/pubmed" id="14726904" target="_blank">14726904</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3492164">
<a name="3492164"></a>Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. <i>Ann Intern Med</i>. 1987;106(2):196-204. doi:10.7326/0003-4819-106-2-196<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/3492164/pubmed" id="3492164" target="_blank">3492164</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17878469">
<a name="17878469"></a>Anzueto A, Sethi S, Martinez FJ. Exacerbations of chronic obstructive pulmonary disease. <i>Proc Am Thorac Soc</i>. 2007;4(7):554-564.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/17878469/pubmed" id="17878469" target="_blank">17878469</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Apprilon.2018.05">
<a name="Apprilon.2018.05"></a>Apprilon (doxycycline) [product monograph]. Thornhill, Ontario, Canada: Galderma Canada Inc; May 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18162038">
<a name="18162038"></a>Ariza J, Bosilkovski M, Cascio A, et al; International Society of Chemotherapy; Institute of Continuing Medical Education of Ioannina. Perspectives for the treatment of brucellosis in the 21st century: the Ioannina recommendations. <i>PLoS Med</i>. 2007;4(12):e317.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/18162038/pubmed" id="18162038" target="_blank">18162038</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Atridox.1">
<a name="Atridox.1"></a>Atridox (doxycycline) controlled-release gel [product monograph]. Niagara on the Lake, Ontario, Canada: Henry Schein; June 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20720371">
<a name="20720371"></a>Azuma N, Hashimoto N, Nishioka A, Sano H. Black thyroid. <i>Intern Med</i>. 2010;49(16):1835-1836. doi:10.2169/internalmedicine.49.3528<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/20720371/pubmed" id="20720371" target="_blank">20720371</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bachmann.1">
<a name="Bachmann.1"></a>Bachmann LH. Urethritis in adult men. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 26, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Berbari.2019">
<a name="Berbari.2019"></a>Baddour LM, Chen AF. Prosthetic joint infection: Treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 31, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Baddour.2019a">
<a name="Baddour.2019a"></a>Baddour LM, Harper M. Animal bites (dogs, cats, and other mammals): evaluation and management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 24, 2024a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Baddour.2019b">
<a name="Baddour.2019b"></a>Baddour LM, Harper M. Human bites: Evaluation and management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 24, 2024b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Baddour.2021c">
<a name="Baddour.2021c"></a>Baddour LM. Impetigo. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 22, 2021c.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36043414">
<a name="36043414"></a>Baddour LM, Weimer MB, Wurcel AG, et al; American Heart Association Rheumatic Fever, Endocarditis and Kawasaki Disease Committee of the Council on Lifelong Congenital Heart Disease and Heart Health in the Young; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; and Council on Peripheral Vascular Disease. Management of infective endocarditis in people who inject drugs: a scientific statement from the American Heart Association. <i>Circulation</i>. 2022;146(14):e187-e201. doi:10.1161/CIR.0000000000001090<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/36043414/pubmed" id="36043414" target="_blank">36043414</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26373317">
<a name="26373317"></a>Baltimore RS, Gewitz M, Baddour LM, et al. Infective endocarditis in childhood: 2015 update: a scientific statement from the American Heart Association (AHA). <i>Circulation</i>. 2015;132(15):1487-1515.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/26373317/pubmed" id="26373317" target="_blank">26373317</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26229122">
<a name="26229122"></a>Berbari EF, Kanj SS, Kowalski TJ, et al; Infectious Diseases Society of America. 2015 Infectious Diseases Society of America (IDSA) clinical practice guidelines for the diagnosis and treatment of native vertebral osteomyelitis in adults. <i>Clin Infect Dis</i>. 2015;61(6):e26-e46.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/26229122/pubmed" id="26229122" target="_blank">26229122</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27172113">
<a name="27172113"></a>Biggs HM, Behravesh CB, Bradley KK, et al. Diagnosis and management of tickborne rickettsial diseases: Rocky Mountain spotted fever and other spotted fever group rickettsioses, ehrlichioses, and anaplasmosis - United States. <i>MMWR Recomm Rep</i>. 2016;65(2):1-44. doi:10.15585/mmwr.rr6502a1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/27172113/pubmed" id="27172113" target="_blank">27172113</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16165719">
<a name="16165719"></a>Björnsson E, Jerlstad P, Bergqvist A, Olsson R. Fulminant drug-induced hepatic failure leading to death or liver transplantation in Sweden. <i>Scand J Gastroenterol</i>. 2005;40(9):1095-1101. doi:10.1080/00365520510023846<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/16165719/pubmed" id="16165719" target="_blank">16165719</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30888626">
<a name="30888626"></a>Blakely KM, Drucker AM, Rosen CF. Drug-induced photosensitivity-An update: Culprit drugs, prevention and management. <i>Drug Saf</i>. 2019;42(7):827-847. doi:10.1007/s40264-019-00806-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/30888626/pubmed" id="30888626" target="_blank">30888626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3709622">
<a name="3709622"></a>Böcker R, Mühlberg W, Platt D, et al. Serum Level, Half-Life and Apparent Volume of Distribution of Doxycycline in Geriatric Patients. <i>Eur J Clin Pharmacol.</i> 1986;30(1):105-108.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/3709622/pubmed" id="3709622" target="_blank">3709622</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3606243">
<a name="3606243"></a>Bonavina L, DeMeester TR, McChesney L, Schwizer W, Albertucci M, Bailey RT. Drug-induced esophageal strictures. <i>Ann Surg</i>. 1987;206(2):173-183. doi:10.1097/00000658-198708000-00010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/3606243/pubmed" id="3606243" target="_blank">3606243</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35766904">
<a name="35766904"></a>Borradori L, Van Beek N, Feliciani C, et al. Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV). <i>J Eur Acad Dermatol Venereol</i>. 2022;36(10):1689-1704. doi:10.1111/jdv.18220<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/35766904/pubmed" id="35766904" target="_blank">35766904</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bosilkovski.2019">
<a name="Bosilkovski.2019"></a>Bosilkovski M. Brucellosis: treatment and prevention. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 26, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33650077">
<a name="33650077"></a>Bosilkovski M, Keramat F, Arapović J. The current therapeutical strategies in human brucellosis. <i>Infection</i>. 2021;49(5):823-832. doi:10.1007/s15010-021-01586-w<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/33650077/pubmed" id="33650077" target="_blank">33650077</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15677845">
<a name="15677845"></a>Bossi P, Tegnell A, Baka A, et al; Taskforce on Bioterrorism (BICHAT), Public Health Directorate, European Commission, Luxembourg. Bichat guidelines for the clinical management of tularaemia and bioterrorism-related tularaemia. <i>Euro Surveill.</i> 2004;9(12):E9-E10.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/15677845/pubmed" id="15677845" target="_blank">15677845</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34734902">
<a name="34734902"></a>Bouferraa Y, Bou Zerdan M, Hamouche R, Azar E, Afif C, Jabbour R. Neurobrucellosis: brief review. <i>Neurologist</i>. 2021;26(6):248-252. doi:10.1097/NRL.0000000000000348<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/34734902/pubmed" id="34734902" target="_blank">34734902</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31834290">
<a name="31834290"></a>Bower WA, Schiffer J, Atmar RL, et al; CDC ACIP Anthrax Vaccine Work Group. Use of anthrax vaccine in the United States: recommendations of the Advisory Committee on Immunization Practices, 2019. <i>MMWR Recomm Rep</i>. 2019;68(4):1-14. doi:10.15585/mmwr.rr6804a1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/31834290/pubmed" id="31834290" target="_blank">31834290</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21880587">
<a name="21880587"></a>Bradley JS, Byington CL, Shah SS, et al. The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. <i>Clin Infect Dis.</i> 2011;53(7):e25-e76.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/21880587/pubmed" id="21880587" target="_blank">21880587</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bradley.2">
<a name="Bradley.2"></a>Bradley JS, Nelson JD, Kimberlin DK, et al, eds. <i>Nelson's Pocket Book of Pediatric Antimicrobial Therapy</i>. 28th ed. American Academy of Pediatrics; 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24777226">
<a name="24777226"></a>Bradley JS, Peacock G, Krug SE, et al. Pediatric anthrax clinical management. <i>Pediatrics</i>. 2014;133(5):1411-1436.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/24777226/pubmed" id="24777226" target="_blank">24777226</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Brook.2020">
<a name="Brook.2020"></a>Brook I. Treatment of actinomycosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 26, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3684731">
<a name="3684731"></a>Bryant SG, Fisher S, Kluge RM. Increased Frequency of Doxycycline Side Effects. <i>Pharmacotherapy.</i> 1987;7(4):125-129.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/3684731/pubmed" id="3684731" target="_blank">3684731</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17388211">
<a name="17388211"></a>Cac NN, Messingham MJ, Sniezek PJ, Walling HW. Stevens-Johnson syndrome induced by doxycycline. <i>Cutis</i>. 2007;79(2):119-122.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/17388211/pubmed" id="17388211" target="_blank">17388211</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14711147">
<a name="14711147"></a>Carroll LA, Laumann AE. Doxycycline-induced photo-onycholysis. <i>J Drugs Dermatol</i>. 2003;2(6):662-663.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/14711147/pubmed" id="14711147" target="_blank">14711147</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.2012">
<a name="CDC.2012"></a>Centers for Disease Control and Prevention (CDC). Brucellosis: Assessing laboratory risk level and PEP. <a href="https://www.cdc.gov/brucellosis/laboratories/risk-level.html" target="_blank">https://www.cdc.gov/brucellosis/laboratories/risk-level.html</a>. Updated November 12, 2012. Accessed August 10, 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.1">
<a name="CDC.1"></a>Centers for Disease Control and Prevention (CDC). Cholera - Vibrio cholerae infection. Antibiotic treatment: recommendations for the use of antibiotics for the treatment of cholera. <a href="https://www.cdc.gov/cholera/treatment/antibiotic-treatment.html" target="_blank">https://www.cdc.gov/cholera/treatment/antibiotic-treatment.html</a>. Updated June 1, 2022a. Accessed September 1, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16572105">
<a name="16572105"></a>Centers for Disease Control and Prevention (CDC). Diagnosis and Management of Tickborne Rickettsial Diseases: Rocky Mountain Spotted Fever, Ehrlichioses, and Anaplasmosis - United States. <i>MMWR Recomm Rep.</i> 2006;55(RR-4):1-27.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/16572105/pubmed" id="16572105" target="_blank">16572105</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.2023">
<a name="CDC.2023"></a>Centers for Disease Control and Prevention (CDC). Guidelines for the use of doxycycline post-exposure prophylaxis for bacterial sexually transmitted infection prevention. <a href="https://www.cdc.gov/std/treatment/guidelines-for-doxycycline.htm" target="_blank">https://www.cdc.gov/std/treatment/guidelines-for-doxycycline.htm</a>. Updated September 29, 2023a. Accessed October 4, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.2020">
<a name="CDC.2020"></a>Centers for Disease Control and Prevention (CDC). Treatment of malaria: guidelines for clinicians (United States). <a href="https://www.cdc.gov/malaria/diagnosis_treatment/clinicians1.html" target="_blank">https://www.cdc.gov/malaria/diagnosis_treatment/clinicians1.html</a>. Updated June 28, 2023b. Accessed July 26, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.2">
<a name="CDC.2"></a>Centers for Disease Control and Prevention (CDC). Treatment of malaria: guidelines for clinicians (United States). <a href="https://www.cdc.gov/malaria/diagnosis_treatment/clinicians1.html" target="_blank">https://www.cdc.gov/malaria/diagnosis_treatment/clinicians1.html</a>. Updated September 30, 2022b. Accessed January 7, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12403408">
<a name="12403408"></a>Centers for Disease Control and Prevention (CDC). Q Fever - California, Georgia, Pennsylvania, and Tennessee, 2000-2001. <i>MMWR Weekly.</i> 2002;51(41):924-927.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/12403408/pubmed" id="12403408" target="_blank">12403408</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.2015">
<a name="CDC.2015"></a>Centers for Disease Control and Prevention (CDC). Recommended antibiotic treatment for plague. 2015. <a href="https://www.cdc.gov/plague/healthcare/clinicians.html" target="_blank">https://www.cdc.gov/plague/healthcare/clinicians.html</a>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.2019">
<a name="CDC.2019"></a>Centers for Disease Control and Prevention (CDC). Tickborne diseases of the United States: Tick bite prophylaxis. 2019. <a href="https://www.cdc.gov/ticks/tickbornediseases/tick-bite-prophylaxis.html" target="_blank">https://www.cdc.gov/ticks/tickbornediseases/tick-bite-prophylaxis.html</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.2022c">
<a name="CDC.2022c"></a>Centers for Disease Control and Prevention (CDC). Tularemia: for clinicians. <a href="https://www.cdc.gov/tularemia/clinicians/index.html" target="_blank">https://www.cdc.gov/tularemia/clinicians/index.html</a>. Updated July 5, 2022c. Accessed September 21, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20651644">
<a name="20651644"></a>Centers for Disease Control and Prevention (CDC). Use of anthrax vaccine in the United States. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. <i>MMWR.</i> 2010;59(6):1-30. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5906a1.htm?s_cid=rr5906a1_e" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/rr5906a1.htm?s_cid=rr5906a1_e</a>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/20651644/pubmed" id="20651644" target="_blank">20651644</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11699843">
<a name="11699843"></a>Centers for Disease Control and Prevention (CDC). Update: Investigation of bioterrorism-related anthrax and interim guidelines for exposure management and antimicrobial therapy, October 2001. <i>MMWR.</i> 2001;50(42):909-919. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5042a1.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5042a1.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/11699843/pubmed" id="11699843" target="_blank">11699843</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11686472">
<a name="11686472"></a>Centers for Disease Control and Prevention (CDC). Update: Investigation of Anthrax Associated with Intentional Exposure and Interim Public Health Guidelines, October 2001. <i>MMWR Morb Mortal Wkly Rep.</i> 2001;50(41):889-893.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/11686472/pubmed" id="11686472" target="_blank">11686472</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34135692">
<a name="34135692"></a>Cherry CC, Kersh GJ. Pediatric Q fever. <i>Curr Infect Dis Rep</i>. 2020;22(4):10.1007/s11908-020-0719-0. doi:10.1007/s11908-020-0719-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/34135692/pubmed" id="34135692" target="_blank">34135692</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22438350">
<a name="22438350"></a>Chow AW, Benninger MS, Brook I, et al; Infections Diseases Society of America. IDSA clinical practice guideline for acute bacterial rhinosinusitis in children and adults. <i>Clin Infect Dis.</i> 2012;54(8):e72-e112.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/22438350/pubmed" id="22438350" target="_blank">22438350</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12431134">
<a name="12431134"></a>Chung AM, Reed MD, Blumer JL. Antibiotics and Breast-Feeding: A Critical Review of the Literature. <i>Paediatr Drugs.</i> 2002;4(12):817-837.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/12431134/pubmed" id="12431134" target="_blank">12431134</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cohlan.1963">
<a name="Cohlan.1963"></a>Cohlan SQ, Bevelander G, Tiamsic T. Growth inhibition of prematures receiving tetracycline. <i>Am J Dis Child</i>. 1963;453-461.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/Cohlan.1963/pubmed" id="Cohlan.1963" target="_blank">Cohlan.1963</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7695265">
<a name="7695265"></a>Colmenero JD, Fernández-Gallardo LC, Agúndez JA, Sedeño J, Benítez J, Valverde E. Possible implications of doxycycline-rifampin interaction for treatment of brucellosis. <i>Antimicrob Agents Chemother</i>. 1994;38(12):2798-2802.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/7695265/pubmed" id="7695265" target="_blank">7695265</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14720410">
<a name="14720410"></a>Cone LA, Leung MM, Hirschberg J. Actinomyces odontolyticus bacteremia. <i>Emerg Infect Dis</i>. 2003;9(12):1629-1632. doi:10.3201/eid0912.020646<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/14720410/pubmed" id="14720410" target="_blank">14720410</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26680308">
<a name="26680308"></a>Cross R, Ling C, Day NP, McGready R, Paris DH. Revisiting doxycycline in pregnancy and early childhood – time to rebuild its reputation? <i>Expert Opin Drug Saf</i>. 2016;15(3):367-382. doi:10.1517/14740338.2016.1133584<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/26680308/pubmed" id="26680308" target="_blank">26680308</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11168126">
<a name="11168126"></a>Cunha BA, Domenico P, Cunha CB. Pharmacodynamics of doxycycline. <i>Clin Microbiol Infect.</i> 2000;6(5):270-273. doi:10.1046/j.1469-0691.2000.00058-2.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/11168126/pubmed" id="11168126" target="_blank">11168126</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19875685">
<a name="19875685"></a>Daniels JM, Snijders D, de Graaff CS, Vlaspolder F, Jansen HM, Boersma WG. Antibiotics in addition to systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. <i>Am J Respir Crit Care Med</i>. 2010;181(2):150-157. doi:10.1164/rccm.200906-0837OC<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/19875685/pubmed" id="19875685" target="_blank">19875685</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9233865">
<a name="9233865"></a>Dattwyler RJ, Luft BJ, Kunkel MJ, et al. Ceftriaxone compared with doxycycline for the treatment of acute disseminated Lyme disease. <i>N Engl J Med</i>. 1997;337(5):289-94. doi:10.1056/NEJM199707313370501<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/9233865/pubmed" id="9233865" target="_blank">9233865</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3842633">
<a name="3842633"></a>Daunt N, Brodribb TR, Dickey JD. Oesophageal Ulceration Due to Doxycycline. <i>Br J Radiol.</i> 1985;58(696):1209-1211.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/3842633/pubmed" id="3842633" target="_blank">3842633</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16168313">
<a name="16168313"></a>Daya M, Nakamura Y. Pulmonary Disease From Biological Agents: Anthrax, Plague, Q Fever, and Tularemia. <i>Crit Care Clin.</i> 2005;21(4):747-763.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/16168313/pubmed" id="16168313" target="_blank">16168313</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1088099">
<a name="1088099"></a>De S, Chaudhuri A, Dutta P, Dutta D, De SP, Pal SC. Doxycycline in the treatment of cholera. <i>Bull World Health Organ</i>. 1976;54(2):177-179.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/1088099/pubmed" id="1088099" target="_blank">1088099</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33282106">
<a name="33282106"></a>Del Rosso JQ, Tanghetti E, Webster G, Stein Gold L, Thiboutot D, Gallo RL. Update on the management of rosacea from the American Acne &amp; Rosacea Society (AARS). <i>J Clin Aesthet Dermatol</i>. 2020;13(6 suppl):S17-S24.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/33282106/pubmed" id="33282106" target="_blank">33282106</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11386933">
<a name="11386933"></a>Dennis DT, Inglesby TV, Henderson DA, et al; Working Group on Civilian Biodefense. Tularemia as a biological weapon: medical and public health management. <i>JAMA</i>. 2001;285(21):2763-2773.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/11386933/pubmed" id="11386933" target="_blank">11386933</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23620467">
<a name="23620467"></a>Deshpande A, Pasupuleti V, Thota P, et al. Community-associated <i>Clostridium difficile</i> infection and antibiotics: a meta-analysis. <i>J Antimicrob Chemother</i>. 2013;68(9):1951-1961. doi:10.1093/jac/dkt129<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/23620467/pubmed" id="23620467" target="_blank">23620467</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Doryx.2020.03">
<a name="Doryx.2020.03"></a>Doryx (doxycycline hyclate) [prescribing information]. Greenville, NC: Mayne Pharma; July 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-DoryxMPC.2020.02">
<a name="DoryxMPC.2020.02"></a>Doryx MPC (doxycycline hyclate delayed release tablets) [prescribing information]. Raleigh, NC: Mayne Pharma; May 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26228938">
<a name="26228938"></a>Dowlati E, Dovico J, Unwin B. Skin hyperpigmentation and melanonychia from chronic doxycycline use. <i>Ann Pharmacother</i>. 2015;49(10):1175-1176. doi:10.1177/1060028015598166<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/26228938/pubmed" id="26228938" target="_blank">26228938</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-DoxycyclineCaps.2022.02">
<a name="DoxycyclineCaps.2022.02"></a>Doxycycline capsules [prescribing information]. Congers, NY: Chartwell RX LLC; February 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-JAMP.1">
<a name="JAMP.1"></a>Doxycycline hyclate capsules [product monograph]. Boucherville, Quebec, Canada: JAMP Pharma Corporation; July 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Doxycycline.3">
<a name="Doxycycline.3"></a>Doxycycline hyclate capsules, suspension, tablets, USP [prescribing information]. Congers, NY: Chartwell Rx LLC; February 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-DoxycyclineDRTabs.2020.02">
<a name="DoxycyclineDRTabs.2020.02"></a>Doxycycline hyclate delayed-release tablets [prescribing information]. Greenville, NC: Mayne Pharma; February 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Doxycyclinehyclate.2016.05">
<a name="Doxycyclinehyclate.2016.05"></a>Doxycycline hyclate tablets, USP [prescribing information]. Philadelphia, PA: Lannett Company; May 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Doxycycline.4">
<a name="Doxycycline.4"></a>Doxycycline hyclate tablets, USP [prescribing information]. Congers, NY: Chartwell RX LLC; February 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Doxy100Inj.2020.02">
<a name="Doxy100Inj.2020.02"></a>Doxy 100 injection (doxycycline) [prescribing information]. Lake Zurich, IL: Fresenius Kabi; February 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Doxy100Inj.2020.06">
<a name="Doxy100Inj.2020.06"></a>Doxy 100 injection (doxycycline) [prescribing information]. Lake Zurich, IL: Fresenius Kabi; June 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Doxytab.2019.07">
<a name="Doxytab.2019.07"></a>Doxytab (doxycycline) [product monograph]. Laval, Quebec, Canada: Pro Doc Ltée: July 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23637225">
<a name="23637225"></a>Eichenfield LF, Krakowski AC, Piggott C, et al. Evidence-based recommendations for the diagnosis and treatment of pediatric acne. <i>Pediatrics</i>. 2013;13(1)(suppl 3):S163-186.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/23637225/pubmed" id="23637225" target="_blank">23637225</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Eyre.2019">
<a name="Eyre.2019"></a>Eyre RC. Evaluation of acute scrotal pain in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 6, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11438895">
<a name="11438895"></a>Fenollar F, Fournier PE, Carrieri MP, et al. Risks Factors and Prevention of Q Fever Endocarditis. <i>Clin Infect Dis.</i> 2001;33(3):312-316.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/11438895/pubmed" id="11438895" target="_blank">11438895</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-13699377">
<a name="13699377"></a>Fields JP. Bulging fontanel: a complication of tetracycline therapy in infants. <i>J Pediatr</i>. 1961;58:74-76. doi:10.1016/s0022-3476(61)80061-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/13699377/pubmed" id="13699377" target="_blank">13699377</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-File.2019">
<a name="File.2019"></a>File TM. Treatment of community-acquired pneumonia in adults in the outpatient setting. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 31, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12821469">
<a name="12821469"></a>Foucault C, Raoult D, Brouqui P. Randomized open trial of gentamicin and doxycycline for eradication of Bartonella quintana from blood in patients with chronic bacteremia. <i>Antimicrob Agents Chemother</i>. 2003;47(7):2204-2207.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/12821469/pubmed" id="12821469" target="_blank">12821469</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3320617">
<a name="3320617"></a>Francke EL, Neu HC. Chloramphenicol and Tetracyclines. <i>Med Clin North Am.</i> 1987;71(6):155-168.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/3320617/pubmed" id="3320617" target="_blank">3320617</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11896769">
<a name="11896769"></a>Friedman IS, Shelton RM, Phelps RG. Minocycline-induced hyperpigmentation of the tongue: successful treatment with the Q-switched ruby laser. <i>Dermatol Surg</i>. 2002;28(3):205-209. doi:10.1046/j.1524-4725.2002.01083.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/11896769/pubmed" id="11896769" target="_blank">11896769</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34391332">
<a name="34391332"></a>Fronek L, Brazen B, Ross R, Miller R. Cervicofacial actinomycosis: a unique diagnostic challenge. <i>Dermatol Online J</i>. 2021;27(7). doi:10.5070/D327754367<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/34391332/pubmed" id="34391332" target="_blank">34391332</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22431798">
<a name="22431798"></a>Geisler WM, Koltun WD, Abdelsayed N, et al. Safety and efficacy of WC2031 versus vibramycin for the treatment of uncomplicated urogenital Chlamydia trachomatis infection: a randomized, double-blind, double-dummy, active-controlled, multicenter trial. <i>Clin Infect Dis</i>. 2012;55(1):82-88.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/22431798/pubmed" id="22431798" target="_blank">22431798</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-GOLD.1">
<a name="GOLD.1"></a>Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for prevention, diagnosis and management of COPD: 2022 report. https://goldcopd.org/2023-gold-report-2/. Updated 2023. Accessed January 30, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-GTFCC.1">
<a name="GTFCC.1"></a>Global Task Force on Cholera Control (GTFCC). Cholera outbreak response field manual. https://www.gtfcc.org/wp-content/uploads/2020/04/gtfcc-cholera-outbreak-response-field-manual.pdf. Published October 2019. Accessed September 1, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28291967">
<a name="28291967"></a>Goetze S, Hiernickel C, Elsner P. Phototoxicity of doxycycline: A systematic review on clinical manifestations, frequency, cofactors, and prevention. <i>Skin Pharmacol Physiol</i>. 2017;30(2):76-80. doi:10.1159/000458761.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/28291967/pubmed" id="28291967" target="_blank">28291967</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27009489">
<a name="27009489"></a>Golub LM, Elburki MS, Walker C, et al. Non-antibacterial tetracycline formulations: host-modulators in the treatment of periodontitis and relevant systemic diseases. <i>Int Dent J</i>. 2016;66(3):127-135. doi:10.1111/idj.12221<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/27009489/pubmed" id="27009489" target="_blank">27009489</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22086858">
<a name="22086858"></a>Gould FK, Denning DW, Elliott TS, et al. Guidelines for the Diagnosis and Antibiotic Treatment of Endocarditis in Adults: A Report of the Working Party of the British Society for Antimicrobial Chemotherapy. <i>J Antimicrob Chemother.</i> 2012;67(2):269-289.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/22086858/pubmed" id="22086858" target="_blank">22086858</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Graber.2020">
<a name="Graber.2020"></a>Graber E. Acne vulgaris: Management of moderate to severe acne in adolescents and adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 3, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31709872">
<a name="31709872"></a>Guo Y, Li HM, Li CX, Zhu WQ, Wang YF, He YH. Oesophageal ulceration in adult patients treated with doxycycline for acne vulgaris. <i>J Int Med Res</i>. 2019;47(12):6404-6409. doi:10.1177/0300060519881272<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/31709872/pubmed" id="31709872" target="_blank">31709872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26785402">
<a name="26785402"></a>Harris AM, Hicks LA, Qaseem A; High Value Care Task Force of the American College of Physicians and for the Centers for Disease Control and Prevention. Appropriate antibiotic use for acute respiratory tract infection in adults: advice for high-value care from the American College of Physicians and the Centers for Disease Control and Prevention. <i>Ann Intern Med</i>. 2016;164(6):425-434. doi:10.7326/M15-1840<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/26785402/pubmed" id="26785402" target="_blank">26785402</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18452690">
<a name="18452690"></a>Hartzell JD, Wood-Morris RN, Martinez LJ, et al. Q Fever: Epidemiology, Diagnosis, and Treatment. <i>Mayo Clin Proc.</i> 2008;83(5):574-579.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/18452690/pubmed" id="18452690" target="_blank">18452690</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16575723">
<a name="16575723"></a>Hasanjani Roushan MR, Mohraz M, Hajiahmadi M, Ramzani A, Valayati AA. Efficacy of gentamicin plus doxycycline versus streptomycin plus doxycycline in the treatment of brucellosis in humans. <i>Clin Infect Dis</i>. 2006;42(8):1075-1080.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/16575723/pubmed" id="16575723" target="_blank">16575723</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27870777">
<a name="27870777"></a>Haskes C, Shea M, Imondi D. Minocycline-induced scleral and dermal hyperpigmentation. <i>Optom Vis Sci</i>. 2017;94(3):436-442. doi:10.1097/OPX.0000000000001024<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/27870777/pubmed" id="27870777" target="_blank">27870777</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17875115">
<a name="17875115"></a>Heaton PC, Fenwick SR, Brewer DE. Association between tetracycline or doxycycline and hepatotoxicity: a population based case-control study. <i>J Clin Pharm Ther</i>. 2007;32(5):483-487. doi:10.1111/j.1365-2710.2007.00853.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/17875115/pubmed" id="17875115" target="_blank">17875115</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19397464">
<a name="19397464"></a>Heintz BH, Matzke GR, Dager WE. Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis. <i>Pharmacotherapy</i>. 2009;29(5):562-577. doi:10.1592/phco.29.5.562<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/19397464/pubmed" id="19397464" target="_blank">19397464</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24447897">
<a name="24447897"></a>Hendricks KA, Wright ME, Shadomy SV, et al; Workgroup on Anthrax Clinical Guidelines. Centers for Disease Control and Prevention expert panel meetings on prevention and treatment of anthrax in adults. <i>Emerg Infect Dis</i>. 2014;20(2):e130687. doi:10.3201/eid2002.130687<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/24447897/pubmed" id="24447897" target="_blank">24447897</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHSPanel.2016">
<a name="HHSPanel.2016"></a>HHS Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection. <a href="https://clinicalinfo.hiv.gov/en/guidelines/pediatric-arv/whats-new" target="_blank">https://clinicalinfo.hiv.gov/en/guidelines/pediatric-arv/whats-new</a>. Updated March 1, 2016. Accessed July 30, 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hicks.2022">
<a name="Hicks.2022"></a>Hicks CB, Clement M. Syphilis: treatment and monitoring. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 31, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6626415">
<a name="6626415"></a>Houin G, Brunner F, Nebout T, Cherfaoui M, Lagrue G, Tillement JP. The effects of chronic renal insufficiency on the pharmacokinetics of doxycycline in man. <i>Br J Clin Pharmacol</i>. 1983;16(3):245-252. doi:10.1111/j.1365-2125.1983.tb02157.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/6626415/pubmed" id="6626415" target="_blank">6626415</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hsu.2022">
<a name="Hsu.2022"></a>Hsu K. Treatment of Chlamydia trachomatis infection. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 10, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hu.2019">
<a name="Hu.2019"></a>Hu L. Treatment of Lyme disease. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 29, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10807389">
<a name="10807389"></a>Inglesby TV, Dennis DT, Henderson DA, et al. Plague as a Biological Weapon: Medical and Public Health Management. Working Group on Civilian Biodefense. <i>JAMA.</i> 2000;283(17):2281-2290.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/10807389/pubmed" id="10807389" target="_blank">10807389</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10328075">
<a name="10328075"></a>Inglesby TV, Henderson DA, Bartlett JG, et al. Anthrax as a Biological Weapon: Medical and Public Health Management. Working Group on Civilian Biodefense. <i>JAMA.</i> 1999;281(18):1735-1745.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/10328075/pubmed" id="10328075" target="_blank">10328075</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28143754">
<a name="28143754"></a>Jia B, Zhang F, Pang P, et al. Brucella endocarditis: Clinical features and treatment outcomes of 10 cases from Xinjiang, China. <i>J Infect</i>. 2017;74(5):512-514. doi:10.1016/j.jinf.2017.01.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/28143754/pubmed" id="28143754" target="_blank">28143754</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Jolkovsky.2006">
<a name="Jolkovsky.2006"></a>Jolkovsky DL, Ciancio S. Chemotherapeutic Agents. In: Newman MG, Takei HH, Klokkevold PR, et al, eds. <i>Clinical Periodontology.</i> 10th ed. Saunders/Elsevier; 2006:802-803.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23887527">
<a name="23887527"></a>Johnston S. Feeling blue? Minocycline-induced staining of the teeth, oral mucosa, sclerae and ears - a case report. <i>Br Dent J</i>. 2013;215(2):71-73. doi:10.1038/sj.bdj.2013.682<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/23887527/pubmed" id="23887527" target="_blank">23887527</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33660281">
<a name="33660281"></a>Jørgensen AR, Yao Y, Thomsen SF, Ring HC. Treatment of hidradenitis suppurativa with tetracycline, doxycycline, or lymecycline: a prospective study.<i> Int J Dermatol.</i> 2021;60(7):785-791. doi:10.1111/ijd.15459<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/33660281/pubmed" id="33660281" target="_blank">33660281</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9224219">
<a name="9224219"></a>Joshi N, Miller DQ. Doxycycline Revisited. <i>Arch Intern Med. </i>1997;157(13):1421-1428.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/9224219/pubmed" id="9224219" target="_blank">9224219</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26219940">
<a name="26219940"></a>Keijmel SP, van Kasteren ME, Blokx WA, van der Meer JW, van Rossum M, Bleeker-Rovers CP. Cutaneous hyperpigmentation induced by doxycycline: a case series. <i>Neth J Med</i>. 2015;73(1):37-40.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/26219940/pubmed" id="26219940" target="_blank">26219940</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kim.2014">
<a name="Kim.2014"></a>Kim SH, Jeon JB, Kim JW, et al. Clinical and endoscopic characteristics of drug-induced esophagitis. <i>World J Gastroenterol</i>. 2014;20(31)10994-10999.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23657872">
<a name="23657872"></a>Kong YL, Tey HL. Treatment of acne vulgaris during pregnancy and lactation. <i>Drugs</i>. 2013;73(8):779-787.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/23657872/pubmed" id="23657872" target="_blank">23657872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17873181">
<a name="17873181"></a>Kvale PA, Selecky, Prakash BS, et al. Palliative Care In Lung Cancer: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition). <i>Chest.</i> 2007;132(suppl 3):268S-403S. doi:10.1378/chest.07-1391<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/17873181/pubmed" id="17873181" target="_blank">17873181</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32211414">
<a name="32211414"></a>Lambert JS. An overview of tickborne infections in pregnancy and outcomes in the newborn: the need for prospective studies. <i>Front Med (Lausanne)</i>. 2020;7:72. doi:10.3389/fmed.2020.00072<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/32211414/pubmed" id="32211414" target="_blank">32211414</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33251700">
<a name="33251700"></a>Lantos PM, Rumbaugh J, Bockenstedt LK, et al. Clinical practice guidelines by the Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR): 2020 guidelines for the prevention, diagnosis, and treatment of lyme disease. <i>Arthritis Care Res (Hoboken)</i>. 2021;73(1):1-9. doi:10.1002/acr.24495<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/33251700/pubmed" id="33251700" target="_blank">33251700</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-263881">
<a name="263881"></a>Lasser AE, Steiner MM. Tetracycline photo-onycholysis. <i>Pediatrics</i>. 1978;61(1):98-99.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/263881/pubmed" id="263881" target="_blank">263881</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8252763">
<a name="8252763"></a>Layton AM, Cunliffe WJ. Phototoxic eruptions due to doxycycline--a dose-related phenomenon. <i>Clin Exp Dermatol</i>. 1993;18(5):425-427. doi:10.1111/j.1365-2230.1993.tb02242.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/8252763/pubmed" id="8252763" target="_blank">8252763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22283782">
<a name="22283782"></a>Lebrun-Vignes B, Kreft-Jais C, Castot A, Chosidow O; French Network of Regional Centers of Pharmacovigilance. Comparative analysis of adverse drug reactions to tetracyclines: results of a French national survey and review of the literature. <i>Br J Dermatol</i>. 2012;166(6):1333-1341. doi:10.1111/j.1365-2133.2012.10845.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/22283782/pubmed" id="22283782" target="_blank">22283782</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4564509">
<a name="4564509"></a>Lee P, Crutch ER, Morrison RB. Doxycycline: studies in normal subjects and patients with renal failure. <i>N Z Med J</i>. 1972;75(481):355-358.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/4564509/pubmed" id="4564509" target="_blank">4564509</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4584946">
<a name="4584946"></a>Letteri JM, Miraflor F, Tablante V, Siddiqi S. Doxycycline (Vibramycin) in chronic renal failure. <i>Nephron</i>. 1973;11(5):318-324.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/4584946/pubmed" id="4584946" target="_blank">4584946</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29073637">
<a name="29073637"></a>Li WQ, Drucker AM, Cho E, et al. Tetracycline use and risk of incident skin cancer: a prospective study. <i>Br J Cancer</i>. 2018;118(2):294-298. doi:10.1038/bjc.2017.378<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/29073637/pubmed" id="29073637" target="_blank">29073637</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Limb.2019">
<a name="Limb.2019"></a>Limb CJ, Lustig LR, Durand ML. Acute otitis media in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 27, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22619242">
<a name="22619242"></a>Lipsky BA, Berendt AR, Cornia PB, et al. 2012 Infectious Diseases Society of America Clinical Practice Guideline for the Diagnosis and Treatment of Diabetic Foot Infections. <i>Clin Infect Dis.</i> 2012;54(12):e132-e173.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/22619242/pubmed" id="22619242" target="_blank">22619242</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21217178">
<a name="21217178"></a>Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant <i>Staphylococcus aureus</i> infections in adults and children: executive summary. <i>Clin Infect Dis</i>. 2011;52(3):285-292.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/21217178/pubmed" id="21217178" target="_blank">21217178</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3296097">
<a name="3296097"></a>Ljungberg B, Nilsson-Ehle I. Pharmacokinetics of Antimicrobial Agents in the Elderly. <i>Rev Infect Dis.</i> 1987;9(2):250-264.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/3296097/pubmed" id="3296097" target="_blank">3296097</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9613662">
<a name="9613662"></a>Lochary ME, Lockhart PB, Williams WT Jr. Doxycycline and staining of permanent teeth. <i>Pediatr Infect Dis J</i>. 1998;17(5):429-431. doi:10.1097/00006454-199805000-00019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/9613662/pubmed" id="9613662" target="_blank">9613662</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37018493">
<a name="37018493"></a>Luetkemeyer AF, Donnell D, Dombrowski JC, et al; DoxyPEP Study Team. Postexposure doxycycline to prevent bacterial sexually transmitted infections. <i>N Engl J Med</i>. 2023;388(14):1296-1306. doi:10.1056/NEJMoa2211934<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/37018493/pubmed" id="37018493" target="_blank">37018493</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Maier.2019">
<a name="Maier.2019"></a>Maier LE. Management of rosacea. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 26, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sexton.2019b">
<a name="Sexton.2019b"></a>McClain MT. Treatment of Rocky Mountain spotted fever. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 6, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31573350">
<a name="31573350"></a>Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. <i>Am J Resp Crit Care Med</i>. 2019;200(7):e45-e67. doi:10.1164/rccm.201908-1581ST<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/31573350/pubmed" id="31573350" target="_blank">31573350</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23794723">
<a name="23794723"></a>Million M, Walter G, Thuny F, Habib G, Raoult D. Evolution from acute Q fever to endocarditis is associated with underlying valvulopathy and age and can be prevented by prolonged antibiotic treatment. <i>Clin Infect Dis</i>. 2013;57(6):836-844. doi:10.1093/cid/cit419<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/23794723/pubmed" id="23794723" target="_blank">23794723</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29229440">
<a name="29229440"></a>Molina JM, Charreau I, Chidiac C, et al; ANRS IPERGAY Study Group. Post-exposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men: an open-label randomised substudy of the ANRS IPERGAY trial. <i>Lancet Infect Dis</i>. 2018;18(3):308-317. doi:10.1016/S1473-3099(17)30725-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/29229440/pubmed" id="29229440" target="_blank">29229440</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-MonodoxyneNL.2015.11">
<a name="MonodoxyneNL.2015.11"></a>Monodoxyne NL (doxycycline) [prescribing information]. Petaluma, CA: IntraDerm Pharmaceuticals; November 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26091383">
<a name="26091383"></a>Moore A, Ling M, Bucko A, Manna V, Rueda MJ. Efficacy and safety of subantimicrobial dose, modified-release doxycycline 40 mg versus doxycycline 100 mg versus placebo for the treatment of inflammatory lesions in moderate and severe acne: a randomized, double-blinded, controlled study. <i>J Drugs Dermatol</i>. 2015;14(6):581-586.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/26091383/pubmed" id="26091383" target="_blank">26091383</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24528911">
<a name="24528911"></a>Murase JE, Heller MM, Butler DC. Safety of dermatologic medications in pregnancy and lactation: part I. Pregnancy. <i>J Am Acad Dermatol</i>. 2014;70(3):e1-14.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/24528911/pubmed" id="24528911" target="_blank">24528911</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Murrell.2023">
<a name="Murrell.2023"></a>Murrell DF, Ramirez-Quizon M. Management and prognosis of bullous pemphigoid. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com/contents/management-and-prognosis-of-bullous-pemphigoid?search=bullous%20pemphigoid&amp;source=search_result&amp;selectedTitle=1~148&amp;usage_type=default&amp;display_rank=1#H2181224722" target="_blank">http://www.uptodate.com</a>. Accessed May 24, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20814687">
<a name="20814687"></a>Mylonas I. Antibiotic Chemotherapy During Pregnancy and Lactation Period: Aspects for Consideration. <i>Arch Gynecol Obstet. </i> 2011;283(1):7-18.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/20814687/pubmed" id="20814687" target="_blank">20814687</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11450675">
<a name="11450675"></a>Nadelman RB, Nowakowski J, Fish D, et al; Tick Bite Study Group. Prophylaxis with single-dose doxycycline for the prevention of Lyme disease after an <i>Ixodes scapularis</i> tick bite. <i>N Engl J Med</i>. 2001;345(2):79-84. doi:10.1056/NEJM200107123450201<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/11450675/pubmed" id="11450675" target="_blank">11450675</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34264565">
<a name="34264565"></a>Nelson CA, Meaney-Delman D, Fleck-Derderian S, Cooley KM, Yu PA, Mead PS; contributors. Antimicrobial treatment and prophylaxis of plague: recommendations for naturally acquired infections and bioterrorism response. <i>MMWR Recomm Rep</i>. 2021;70(3):1-27. doi:10.15585/mmwr.rr7003a1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/34264565/pubmed" id="34264565" target="_blank">34264565</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28315732">
<a name="28315732"></a>Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>J Am Coll Cardiol</i>. 2017;70(2):252-289. doi:10.1016/j.jacc.2017.03.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/28315732/pubmed" id="28315732" target="_blank">28315732</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24416755">
<a name="24416755"></a>Olson JM, Vary JC Jr. Primary cutaneous Actinomyces neuii infection of the breast successfully treated with doxycycline. <i>Cutis</i>. 2013;92(6):E3-E4.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/24416755/pubmed" id="24416755" target="_blank">24416755</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-13940207">
<a name="13940207"></a>Opfer K. The bulging fontanelle. <i>Lancet</i>. 1963;1(7272):116. doi:10.1016/s0140-6736(63)91135-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/13940207/pubmed" id="13940207" target="_blank">13940207</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Oracea.2017.08">
<a name="Oracea.2017.08"></a>Oracea (doxycycline) [prescribing information]. Fort Worth, TX: Galderma Laboratories LP; December 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23223583">
<a name="23223583"></a>Osmon DR, Berbari EF, Berendt AR, et al. Diagnosis and Management of Prosthetic Joint Infection: Clinical Practice Guideline by the Infectious Diseases Society of America. <i>Clin Infect Dis.</i> 2013;56(1):e1-e25.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/23223583/pubmed" id="23223583" target="_blank">23223583</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24015834">
<a name="24015834"></a>Pazzaglia M, Venturi M, Tosti A. Photo-onycholysis caused by an unusual beach game activity: a pediatric case of a side effect caused by doxycycline. <i>Pediatr Dermatol</i>. 2014;31(1):e26-e27. doi:10.1111/pde.12223<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/24015834/pubmed" id="24015834" target="_blank">24015834</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8436641">
<a name="8436641"></a>Pepine M, Flowers FP, Ramos-Caro FA. Extensive cutaneous hyperpigmentation caused by minocycline. <i>J Am Acad Dermatol</i>. 1993;28(2 Pt 2):292-295. doi:10.1016/0190-9622(93)70037-t<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/8436641/pubmed" id="8436641" target="_blank">8436641</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Periostat.2018.11">
<a name="Periostat.2018.11"></a>Periostat (doxycycline hyclate capsules, USP 20 mg) [product monograph]. Montreal, Quebec, Canada: PENDOPHARM; November 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16404570">
<a name="16404570"></a>Porcel JM, Salud A, Nabal M, et al. Rapid Pleurodesis With Doxycycline Through a Small-Bore Catheter for the Treatment of Metastatic Malignant Effusions. <i>Support Care Cancer. </i>2006;14(5):475-478.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/16404570/pubmed" id="16404570" target="_blank">16404570</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Powell.1">
<a name="Powell.1"></a>Powell AM, Nyirjesy P. Acute cervicitis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 26, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Poyhonen.2017">
<a name="Poyhonen.2017"></a>Pöyhönen H, Nurmi M, Peltola V, Alaluusua S, Ruuskanen O, Lähdesmäki T. Dental staining after doxycycline use in children. <i>J Antimicrob Chemother</i>. 2017;72:2887-2890. doi:10.1093/jac/dkx245</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6145571">
<a name="6145571"></a>Raeder JC. Anaphylactoid reaction caused by intravenous doxycycline during general anesthesia and beta-blockade treatment. <i>Drug Intell Clin Pharm</i>. 1984;18(6):481-482. doi:10.1177/106002808401800606<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/6145571/pubmed" id="6145571" target="_blank">6145571</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1298559">
<a name="1298559"></a>Rams TE, Slots J. Antibiotics in Periodontal Therapy: An Update. <i>Compendium.</i> 1992;13(12):1130, 1132, 1134.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/1298559/pubmed" id="1298559" target="_blank">1298559</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8494419">
<a name="8494419"></a>Robinson LA, Fleming WH, Galbraith TA. Intrapleural doxycycline control of malignant pleural effusions. <i>Ann Thorac Surg</i>. 1993;55(5):1115-1121; discussion 1121-1122.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/8494419/pubmed" id="8494419" target="_blank">8494419</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30191155">
<a name="30191155"></a>Rojas-Moreno C, Bhartee H, Vasudevan A, Adiga R, Salzer W. Tetracyclines for treatment of tularemia: a case series. <i>Open Forum Infect Dis</i>. 2018;5(9):ofy176. doi:10.1093/ofid/ofy176<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/30191155/pubmed" id="30191155" target="_blank">30191155</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15155180">
<a name="15155180"></a>Rolain JM, Brouqui P, Koehler JE, Maguina C, Dolan MJ, Raoult D. Recommendations for treatment of human infections caused by Bartonella species. <i>Antimicrob Agents Chemother</i>. 2004;48(6):1921-1933.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/15155180/pubmed" id="15155180" target="_blank">15155180</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25832968">
<a name="25832968"></a>Rosenfeld RM, Piccirillo JF, Chandrasekhar SS, et al. Clinical practice guideline (update): adult sinusitis. <i>Otolaryngol Head Neck Surg.</i> 2015;152(2 suppl):S1-S39. doi:10.1177/0194599815572097<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/25832968/pubmed" id="25832968" target="_blank">25832968</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17945043">
<a name="17945043"></a>Ross J, Judlin P, Nilas L. European Guideline for the Management of Pelvic Inflammatory Disease. <i>Int J STD AIDS.</i> 2007;18(10):662-666. http://std.sagepub.com/content/18/10/662.full.pdf+html. Accessed May 15, 2013.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/17945043/pubmed" id="17945043" target="_blank">17945043</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-RCOG.2015">
<a name="RCOG.2015"></a>Royal College of Obstetricians and Gynaecologists (RCOG). Best practice in comprehensive abortion care. Best Practice Paper No. 2 https://www.rcog.org.uk/en/guidelines-research-services/guidelines/bpp2/. June 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28938256">
<a name="28938256"></a>Sachs N, Atiya-Nasagi Y, Beth-Din A, et al. Chronic Q fever infections in Israeli children: a 25-year nationwide study. <i>Pediatr Infect Dis J</i>. 2018;37(3):212-217. doi:10.1097/INF.0000000000001790<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/28938256/pubmed" id="28938256" target="_blank">28938256</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-708024">
<a name="708024"></a>Sack DA, Islam S, Rabbani H, Islam A. Single-dose doxycycline for cholera. <i>Antimicrob Agents Chemother</i>. 1978;14(3):462-464. doi:10.1128/AAC.14.3.462<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/708024/pubmed" id="708024" target="_blank">708024</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3072140">
<a name="3072140"></a>Saivin S, Hovin G. Clinical Pharmacokinetics of Doxycycline and Minocycline. <i>Clin Pharmacokinet.</i> 1985;15:355-366.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/3072140/pubmed" id="3072140" target="_blank">3072140</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16243127">
<a name="16243127"></a>Sanchez J, Somolinos AL, Almodóvar PI, Webster G, Bradshaw M, Powala C. A randomized, double-blind, placebo-controlled trial of the combined effect of doxycycline hyclate 20-mg tablets and metronidazole 0.75% topical lotion in the treatment of rosacea. <i>J Am Acad Dermatol</i>. 2005;53(5):791-797.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/16243127/pubmed" id="16243127" target="_blank">16243127</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4028871">
<a name="4028871"></a>Schreiner A, Digranes A. Pharmacokinetics of lymecycline and doxycycline in serum and suction blister fluid. <i>Chemotherapy</i>. 1985;31(4):261-265. doi:10.1159/000238345<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/4028871/pubmed" id="4028871" target="_blank">4028871</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19038881">
<a name="19038881"></a>Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. <i>N Engl J Med</i>. 2008;359(22):2355-2365. doi:10.1056/NEJMra0800353<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/19038881/pubmed" id="19038881" target="_blank">19038881</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9382560">
<a name="9382560"></a>Shapiro LE, Knowles SR, Shear NH. Comparative safety of tetracycline, minocycline, and doxycycline. Arch Dermatol. 1997;133(10):1224-1230.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/9382560/pubmed" id="9382560" target="_blank">9382560</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19188870">
<a name="19188870"></a>Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/19188870/pubmed" id="19188870" target="_blank">19188870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3342661">
<a name="3342661"></a>Sherman S, Ravikrishnan KP, Patel AS, Seidman JC. Optimum anesthesia with intrapleural lidocaine during chemical pleurodesis with tetracycline. <i>Chest</i>. 1988;93(3):533-536. doi:10.1378/chest.93.3.533<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/3342661/pubmed" id="3342661" target="_blank">3342661</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32839167">
<a name="32839167"></a>Shute L, Walkty A, Embil JM. Minocycline-induced cutaneous hyperpigmentation. <i>CMAJ</i>. 2020;192(34):E981. doi:10.1503/cmaj.200012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/32839167/pubmed" id="32839167" target="_blank">32839167</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23649452">
<a name="23649452"></a>Simoff MJ, Lally B, Slade MG, et al. Symptom management in patients with lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. <i>Chest</i>. 2013;143(5 suppl):e455S-e497S. doi:10.1378/chest.12-2366<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/23649452/pubmed" id="23649452" target="_blank">23649452</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18321957">
<a name="18321957"></a>Skalsky K, Yahav D, Bishara J, Pitlik S, Leibovici L, Paul M. Treatment of human brucellosis: systematic review and meta-analysis of randomised controlled trials. <i>BMJ</i>. 2008;336(7646):701-704. doi:10.1136/bmj.39497.500903.25<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/18321957/pubmed" id="18321957" target="_blank">18321957</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12707093">
<a name="12707093"></a>Skidmore R, Kovach R, Walker C, et al. Effects of subantimicrobial-dose doxycycline in the treatment of moderate acne. <i>Arch Dermatol</i>. 2003;139(4):459-464.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/12707093/pubmed" id="12707093" target="_blank">12707093</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1749296">
<a name="1749296"></a>Smilack JD, Wilson WR, Cockerill FR 3rd. Tetracyclines, Chloramphenicol, Erythromycin, Clindamycin, and Metronidazole. <i>Mayo Clin Proc.</i> 1991;66(12):1270-1280.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/1749296/pubmed" id="1749296" target="_blank">1749296</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26113100">
<a name="26113100"></a>Smiley CJ, Tracy SL, Abt E, et al. Evidence-based clinical practice guideline on the nonsurgical treatment of chronic periodontitis by means of scaling and root planing with or without adjuncts. <i>J Am Dent Assoc</i>. 2015;146(7):525-535. doi:10.1016/j.adaj.2015.01.026<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/26113100/pubmed" id="26113100" target="_blank">26113100</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21742582">
<a name="21742582"></a>Smirnova MV, Strukova EN, Portnoy YA, et al. The antistaphylococcal pharmacodynamics of linezolid alone and in combination with doxycycline in an in vitro dynamic model. <i>J Chemother.</i> 2011;23(3):140-144. doi:10.1179/joc.2011.23.3.140<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/21742582/pubmed" id="21742582" target="_blank">21742582</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32414479">
<a name="32414479"></a>Smith GN, Moore KM, Hatchette TF, Nicholson J, Bowie W, Langley JM. Committee Opinion No. 399: Management of tick bites and Lyme disease during pregnancy. <i>J Obstet Gynaecol Can</i>. 2020;42(5):644-653. doi:10.1016/j.jogc.2020.01.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/32414479/pubmed" id="32414479" target="_blank">32414479</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Spach.3">
<a name="Spach.3"></a>Spach DH. Bartonella infections in people with HIV. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 2, 2022c.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Spach.2019a">
<a name="Spach.2019a"></a>Spach DH. Clinical features, diagnosis, and treatment of Bartonella quintana infections. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 2, 2022a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Spach.2019b">
<a name="Spach.2019b"></a>Spach DH. Endocarditis caused by Bartonella. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 25, 2022b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Spelman.2">
<a name="Spelman.2"></a>Spelman D, Baddour LM. Skin abscesses in adults: treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 24, 2023a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Spelman.2022">
<a name="Spelman.2022"></a>Spelman D, Baddour LM. Acute cellulitis and erysipelas in adults: Treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 24, 2023b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33332296">
<a name="33332296"></a>St. Cyr S, Barbee L, Workowski KA, et al. Update to CDC's treatment guidelines for gonococcal infection, 2020. <i>MMWR Morb Mortal Wkly Rep</i>. 2020;69(50):1911-1916. doi:10.15585/mmwr.mm6950a6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/33332296/pubmed" id="33332296" target="_blank">33332296</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34348742">
<a name="34348742"></a>Steadman W, Brown Z, Wall CJ. Minocycline black bone disease in arthroplasty: a systematic review. <i>J Orthop Surg Re</i>s. 2021;16(1):479. doi:10.1186/s13018-021-02617-w. Erratum in: <i>J Orthop Surg Res</i>. 2022;17(1):295.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/34348742/pubmed" id="34348742" target="_blank">34348742</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18394267">
<a name="18394267"></a>Stern EJ, Uhde KB, Shadomy SV, et al. Conference Report on Public Health and Clinical Guidelines for Anthrax. <i>Emerg Infect Dis.</i> 2008;14(4). <a href="https://wwwnc.cdc.gov/eid/article/14/4/07-0969.htm" target="_blank">http://wwwnc.cdc.gov/eid/article/14/4/07-0969.htm</a>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/18394267/pubmed" id="18394267" target="_blank">18394267</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24947530">
<a name="24947530"></a>Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2014;59(2):147-159. doi:10.1093/cid/ciu296<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/24947530/pubmed" id="24947530" target="_blank">24947530</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sexton.2019a">
<a name="Sexton.2019a"></a>Stout J. Clinical manifestations, diagnosis, and treatment of plague (Yersinia pestis infection). Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 21, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31280586">
<a name="31280586"></a>Stultz JS, Eiland LS. Doxycycline and tooth discoloration in children: changing of recommendations based on evidence of safety. <i>Ann Pharmacother</i>. 2019;53(11):1162-1166. doi:10.1177/1060028019863796<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/31280586/pubmed" id="31280586" target="_blank">31280586</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22523260">
<a name="22523260"></a>Stupica D, Lusa L, Ruzić-Sabljić E, Cerar T, Strle F. Treatment of erythema migrans with doxycycline for 10 days versus 15 days. <i>Clin Infect Dis</i>. 2012;55(3):343-350. doi:10.1093/cid/cis402<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/22523260/pubmed" id="22523260" target="_blank">22523260</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Tan.2020">
<a name="Tan.2020"></a>Tan KR, Arguin PM. Travel-related infectious diseases: Malaria. In: CDC Yellow Book 2020: Health Information for International Travel. Centers for Disease Control and Prevention (CDC). <a href="https://wwwnc.cdc.gov/travel/yellowbook/2020/travel-related-infectious-diseases/malaria" target="_blank">https://wwwnc.cdc.gov/travel/yellowbook/2020/travel-related-infectious-diseases/malaria</a>. Last reviewed July 1, 2019. Accessed April 24, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Targadox.2019.01">
<a name="Targadox.2019.01"></a>Targadox (doxycycline) [prescribing information]. Scottsdale, AZ: Journey Medical Corporation; January 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29401273">
<a name="29401273"></a>Tariq R, Cho J, Kapoor S, et al. Low risk of primary <i>Clostridium difficile</i> infection with tetracyclines: A systematic review and metaanalysis. <i>Clin Infect Dis</i>. 2018;66(4):514-522. doi:10.1093/cid/cix833<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/29401273/pubmed" id="29401273" target="_blank">29401273</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31548185">
<a name="31548185"></a>Thompson EJ, Wu H, Melloni C, et al. Population pharmacokinetics of doxycycline in children. <i>Antimicrob Agents Chemother</i>. Published online September 23, 2019. doi:10.1128/AAC.01508-19<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/31548185/pubmed" id="31548185" target="_blank">31548185</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25794784">
<a name="25794784"></a>Todd SR, Dahlgren FS, Traeger MS, et al. No visible dental staining in children treated with doxycycline for suspected Rocky Mountain Spotted Fever. <i>J Pediatr</i>. 2015;166(5):1246-1251.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/25794784/pubmed" id="25794784" target="_blank">25794784</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33094412">
<a name="33094412"></a>Tsentemeidou A, Sotiriou E, Vakirlis E, Sideris N, Lallas A, Ioannides D. Treatment strategies for hidradenitis suppurativa: real-life data from a tertiary Greek hospital. <i>Arch Dermatol Res</i>. 2022;314(3):301-305. doi:10.1007/s00403-020-02150-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/33094412/pubmed" id="33094412" target="_blank">33094412</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-USHHS.2015">
<a name="USHHS.2015"></a>US Department of Health and Human Services (HHS) Panel on Opportunistic Infections in Adults and Adolescents With HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. <a href="https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-oi/guidelines-adult-adolescent-oi.pdf" target="_blank">https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-oi/guidelines-adult-adolescent-oi.pdf</a>. Updated September 28, 2022. Accessed November 17, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Vibramycin.2017.08">
<a name="Vibramycin.2017.08"></a>Vibramycin (doxycycline oral) [prescribing information]. New York; NY: Pfizer; received August 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-VibramycinInj.2017.07">
<a name="VibramycinInj.2017.07"></a>Vibramycin (doxycycline injection) [prescribing information]. New York; NY: Pfizer; July 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-VibramycinCaps.2015.12">
<a name="VibramycinCaps.2015.12"></a>Vibramycin Capsules (doxycycline) [product monograph]. Kirkland, Quebec, Canada: Pfizer Canada Inc; December 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-VibramycinSyrup.2019.12">
<a name="VibramycinSyrup.2019.12"></a>Vibramycin Calcium Syrup (doxycycline calcium) [prescribing information]. New York; NY: Pfizer Labs; December 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-VibramycinHycl.2019.12">
<a name="VibramycinHycl.2019.12"></a>Vibramycin Hyclate Capsules (doxycycline hyclate) [prescribing information]. New York; NY: Pfizer Labs; December 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-VibramycinMono.2019.12">
<a name="VibramycinMono.2019.12"></a>Vibramycin Monohydrate for Oral Suspension (doxycycline monohydrate) [prescribing information]. New York; NY: Pfizer Labs; December 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-VibraTabs.2019.12">
<a name="VibraTabs.2019.12"></a>Vibra-Tabs Film Coated Tablets (doxycycline hyclate) [prescribing information]. New York; NY: Pfizer Labs; December 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31237104">
<a name="31237104"></a>Vural S, Gündoğdu M, Akay BN, et al. Hidradenitis suppurativa: Clinical characteristics and determinants of treatment efficacy. <i>Dermatol Ther</i>. 2019;32(5):e13003. doi:10.1111/dth.13003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/31237104/pubmed" id="31237104" target="_blank">31237104</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29665357">
<a name="29665357"></a>White KO, Jones HE, Shorter J, et al. Second-trimester surgical abortion practices in the United States. <i>Contraception</i>. 2018:S0010-7824(18)30140-9. doi:10.1016/j.contraception.2018.04.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/29665357/pubmed" id="29665357" target="_blank">29665357</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30125557">
<a name="30125557"></a>White KO, Jones HE, Lavelanet A, et al. First-trimester aspiration abortion practices: a survey of United States abortion providers. <i>Contraception</i>. 2019;99(1):10-15. doi:10.1016/j.contraception.2018.08.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/30125557/pubmed" id="30125557" target="_blank">30125557</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Wilcox.2021">
<a name="Wilcox.2021"></a>Wilcox CM. Evaluation of anorectal symptoms in men who have sex with men. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 31, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36052413">
<a name="36052413"></a>Wildenthal JA, Atkinson A, Lewis S, et al. Outcomes of partial oral antibiotic treatment for complicated Staphylococcus aureus bacteremia in people who inject drugs. <i>Clin Infect Dis</i>. 2023;76(3):487-496. doi:10.1093/cid/ciac714<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/36052413/pubmed" id="36052413" target="_blank">36052413</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28279484">
<a name="28279484"></a>Williams HC, Wojnarowska F, Kirtschig G, et al; UK Dermatology Clinical Trials Network BLISTER Study Group. Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial. <i>Lancet</i>. 2017;389(10079):1630-1638. doi:10.1016/S0140-6736(17)30560-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/28279484/pubmed" id="28279484" target="_blank">28279484</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29790841">
<a name="29790841"></a>Williams PCM, Berkley JA. Guidelines for the management of paediatric cholera infection: a systematic review of the evidence. <i>Paediatr Int Child Health</i>. 2018;38(Supp 1):S16-S31. doi:10.1080/20469047.2017.1409452<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/29790841/pubmed" id="29790841" target="_blank">29790841</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Wilson.1">
<a name="Wilson.1"></a>Wilson KH. Prevention of anthrax. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 21, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3657308">
<a name="3657308"></a>Wilson WR, Cockerill FR 3rd. Tetracyclines, Chloramphenicol, Erythromycin, and Clindamycin. <i>Mayo Clin Proc.</i> 1987;62(10):906-915.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/3657308/pubmed" id="3657308" target="_blank">3657308</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33853363">
<a name="33853363"></a>Wilson WR, Gewitz M, Lockhart PB, et al; American Heart Association Young Hearts Rheumatic Fever, Endocarditis and Kawasaki Disease Committee of the Council on Lifelong Congenital Heart Disease and Heart Health in the Young; Council on Cardiovascular and Stroke Nursing; and the Council on Quality of Care and Outcomes Research. Prevention of viridans group streptococcal infective endocarditis: a scientific statement from the American Heart Association. <i>Circulation</i>. 2021;143(20):e963-e978. doi:10.1161/CIR.0000000000000969<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/33853363/pubmed" id="33853363" target="_blank">33853363</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17446442">
<a name="17446442"></a>Wilson W, Taubert KA, Gewitz M,et al. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. <i>Circulation</i>. 2007;116(15):1736-1754. doi:10.1161/CIRCULATIONAHA.106.183095<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/17446442/pubmed" id="17446442" target="_blank">17446442</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34292926">
<a name="34292926"></a>Workowski KA, Bachmann LH, Chan PA, et al. Sexually transmitted infections treatment guidelines, 2021. <i>MMWR Recomm Rep</i>. 2021;70(4):1-187. doi:10.15585/mmwr.rr7004a1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/34292926/pubmed" id="34292926" target="_blank">34292926</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26042815">
<a name="26042815"></a>Workowski KA, Bolan GA; Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. <i>MMWR Recomm Rep</i>. 2015;64(RR-03):1-137.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/26042815/pubmed" id="26042815" target="_blank">26042815</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.2002">
<a name="WHO.2002"></a>World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the Eleventh WHO Model List of Essential Drugs. https://apps.who.int/iris/handle/10665/62435. Published 2002.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.2006">
<a name="WHO.2006"></a>World Health Organization. Brucellosis in humans and animals. 2006. http://www.who.int/csr/resources/publications/Brucellosis.pdf.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.2010">
<a name="WHO.2010"></a>World Health Organization (WHO) Global Task Force on Cholera Control. First steps for managing an outbreak of acute diarrhoea. http://www.who.int/cholera/publications/firststeps/en/. Updated November 2010. Accessed July 25, 2013.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.2020">
<a name="WHO.2020"></a>World Health Organization (WHO). WHO guidelines for malaria (2023). https://www.who.int/publications/i/item/guidelines-for-malaria. Published March 14, 2023. Accessed July 20, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17029130">
<a name="17029130"></a>Wormser GP, Dattwyler RJ, Shapiro ED, et al. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2006;43(9):1089-1134. doi:10.1086/508667<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/17029130/pubmed" id="17029130" target="_blank">17029130</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12729423">
<a name="12729423"></a>Wormser GP, Ramanathan R, Nowakowski J, et al. Duration of antibiotic therapy for early Lyme disease. A randomized, double-blind, placebo-controlled trial. <i>Ann Intern Med</i>. 2003;138(9):697-704.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/12729423/pubmed" id="12729423" target="_blank">12729423</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30442509">
<a name="30442509"></a>Wormser GP, Wormser RP, Strle F, Myers R, Cunha BA. How safe is doxycycline for young children or for pregnant or breastfeeding women? <i>Diagn Microbiol Infect Dis</i>. 2019;93(3):238-242. doi:10.1016/j.diagmicrobio.2018.09.015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/30442509/pubmed" id="30442509" target="_blank">30442509</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8513046">
<a name="8513046"></a>Wyler DJ. Malaria: Overview and Update. <i>Clin Infect Dis.</i> 1993;16(4):449-456.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/8513046/pubmed" id="8513046" target="_blank">8513046</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26897386">
<a name="26897386"></a>Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for the management of acne vulgaris. <i>J Am Acad Dermatol. </i>2016;74(5):945-973.e33. http://www.jaad.org/article/S0190-9622(15)02614-6/pdf.
                     <span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/26897386/pubmed" id="26897386" target="_blank">26897386</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30287313">
<a name="30287313"></a>Zakhem GA, Motosko CC, Mu EW, Ho RS. Infertility and teratogenicity after paternal exposure to systemic dermatologic medications: A systematic review. <i>J Am Acad Dermatol</i>. 2019;80(4):957-969. doi:10.1016/j.jaad.2018.09.031<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/30287313/pubmed" id="30287313" target="_blank">30287313</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28768443">
<a name="28768443"></a>Zheng N, Wang W, Zhang JT, et al. Neurobrucellosis. <i>Int J Neurosci</i>. 2018;128(1):55-62. doi:10.1080/00207454.2017.1363747<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/doxycycline-pediatric-drug-information/abstract-text/28768443/pubmed" id="28768443" target="_blank">28768443</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 13255 Version 885.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
